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1.1 Functions and structure of mitochondria 
 
Mitochondria are organelles of eukaryotic cells, which are known for their ability to 
convert chemical energy of lipids, amino acids and monosaccharides to a 
metabolically usable form by oxidative phosphorylation (OXPHOS). Besides the 
function of generating adenosine triphosphate (ATP) by respiration, mitochondria 
fulfill various metabolic functions, such as the metabolism of lipids and amino acids, 
formation of iron-sulfur clusters and heme, urea cycle and calcium homeostasis 
(Dudek et al., 2019; Friedman et al., 2011; Lill and Mühlenhoff, 2008). The exertion 
of all mitochondrial functions requires a conserved compartmentation by inner 
mitochondrial membrane (IMM) and outer mitochondrial membranes (OMM). The 
OMM connects mitochondria to other cell organelles, such as plasma membrane, 
lysosome, peroxisome, lipid droplets and endo- or sarcoplasmic reticulum (ER) via 
formation of contact sites (Elbaz-Alon et al., 2014). These contact sites facilitate 
intracellular communication and an exchange of lipids and small solute molecules 
(Tatsuta et al., 2016). Furthermore, mitochondria are partitioned in two 
compartments, the mitochondrial matrix and the intermembrane space (IMS), 
separated by the IMM. The IMM presents in two different morphological shapes. It 
forms invaginations, called cristae, where OXPHOS protein complexes reside. 
Additionally, the inner boundary membrane, which is in proximity to the OMM, 
localizes the translocases of the protein import machineries (Dudek et al., 2018). The 
compartmentation by the IMM allows the generation of a membrane potential as the 
crucial driving force for all mitochondrial functions (ATP production, mitochondrial 
protein import and biogenesis, etc.). The specific morphology of IMM as well as the 
well-orchestrated functional diversity of mitochondria requires the special 
phospholipid composing mitochondrial membranes known as cardiolipin. This 
dimeric phospholipid resides specifically in inner mitochondrial membrane and is 
involved in various mitochondrial functions, which are introduced in the following 
chapters.  
 
1.2 Cardiolipin: a crucial phospholipid for structural integrity and function of 
mitochondria 
 
The structural and functional role of lipids in biological membranes in eukaryotic 
cells has been extensively studied within the last decades. However, the composition 
of mitochondrial membranes and their crucial role for mitochondrial functions 
received less attention (Saric et al., 2016). Meanwhile, the role of phospholipids in 
mitochondrial membranes were highlighted in signaling pathways in connection with 
mitophagy, apoptosis and cell cycle regulation. The participation of membranes in 
cellular processes requires special properties including fluidity, lateral mobility and 
curvature maintenance (Kagan et al., 2014). In general, biological membranes in 
eukaryotic cells are composed of amphiphilic phospholipid bilayers. The head is the 
hydrophilic phosphate group esterified with two hydrophobic acyl chains (Colina-
Tenorio et al., 2020; Kagan et al., 2014). Mitochondrial membranes reveal differences 
in their phospholipid composition in comparison to other organelle membranes, 
enabling the crucial mitochondrial functions. In fact, the phospholipid-to-protein ratio 
is reduced compared to other cell organelles. The phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) content is exceptionally high in mitochondrial membranes 
and both phospholipids account for 80% of the total membrane phospholipid pool 
(Saric et al., 2016). Additional properties of mitochondrial membranes are the low 
levels of sphingolipids and sterols, but one particular phospholipid shows a strong 
enrichment in mitochondria and is indispensable for its function: Bis-(1,2-diacyl-sn-
glycero-3-phospho)-1´-3´-sn-glycerol or cardiolipin, which is the hallmark 
polyglycerophospholipid in mitochondrial membranes in mammalian cells (Horvath 
and Daum, 2013). Cardiolipin owes its name from the first isolation from beef heart 
(Pangborn, 1946) and its biosynthesis pathway in mammalian cells was elucidated in 
rat liver (Hostetler et al., 1971). Cardiolipin was particularly found in the inner 
mitochondrial membrane and lesser in the outer mitochondrial membrane (Hovius et 
al., 1990, 1993). It has also been observed in mitochondrial contact sites (MCS), 
where the outer and inner mitochondrial membrane come to a proximal contact 
enabling variable functions in the regulation of cellular trafficking, apoptosis, immune 
response and organelle dynamics (Nicolay et al., 1990). Cardiolipin contains a 
glycerol backbone connected with two phosphatidylglycerols, forming a dimeric 
structure (Dudek et al., 2016; Hoch et al., 1992; Maguire et al., 2016). Each 
phosphatidylglycerol is esterified with two acyl chains, hence, the hydrophobic tail is 
composed of four acyl chains. The acyl chains in completely remodeled cardiolipin 
are unsaturated. The variety of cardiolipin species is reasoned by the diversity of 
mono- and polyunsaturated fatty acids in eukaryotic cells. In fact, bacterial and 
eukaryotic cardiolipins differ in two aspects. The acyl chains of cardiolipin differ in 
the degree of saturation and the chain length. Eukaryotic cardiolipins are 
polyunsaturated and longer (18-22 carbon atoms) than cardiolipins from prokaryotes, 
which are saturated or mono-unsaturated and have a shorter chain length. These 
differences were caused by the adaption from anaerobic to aerobic metabolism in the 
evolution from prokaryotes to eukaryotic cells. The double bonds of unsaturated acyl 
chains were oxidized by molecular oxygen, with the result that cardiolipin in 
mitochondria participates in signaling pathways (Saric et al., 2016; Tyurina et al., 
2014). The predominant form in the mammalian heart is tetra-linoleic acid (Hoch et 
al., 1992). Impairments in the processes of cardiolipin biogenesis and remodeling 
cause severe pathophysiological disorders like Barth syndrome (Dudek et al., 2016, 
2018).  
To understand the unique role of cardiolipin in mitochondrial functions compared to 
the other phospholipids, it is worth considering the biogenesis and remodeling process 
of cardiolipin.  
 
1.3 Cardiolipin – biosynthesis, remodeling and degradation 
 
1.3.1 Cardiolipin biosynthesis  
 
The majority of the phospholipids phosphatidylethanolamine (PE), phosphatidylserine 
(PS) and phosphatidic acid (PA) are synthesized in the endoplasmatic reticulum (ER) 
(Hatch et al., 2004; Horvath and Daum, 2013). In contrast, cardiolipin is exclusively 
synthesized in the inner mitochondrial membrane (Kagan et al., 2014; Mejia et al., 
2014).  
Newly synthesized phospholipids can be transported to mitochondrial membranes 
serving as precursors for membrane formation and precursors of cardiolipin 
biosynthesis (Connerth et al., 2012; Tamura et al., 2009). Cardiolipin biosynthesis in 
mitochondrial membranes is evolutionary conserved in eukaryotic cells (Schlame and 
Halder, 1993).  
 
  
Figure 1.1: The different steps of cardiolipin biosynthesis and remodeling (Dudek et al., 
2018). Cardiolipin biosynthesis takes place exclusively in mitochondrial membranes. Newly 
synthetized cardiolipin needs to undergo a remodeling process enabled mainly by the 
transacylase tafazzin, but MLCLA1 and ALCAT1 as well. IM: inner membrane, OM: outer 
membrane, IMS: intermembrane space, PUFA: poly unsaturated fatty acids, pCL: pre-
cardiolipin, mCL: mature cardiolipin 
 
Enzymes involved in cardiolipin biosynthesis pathway are located in the inner leaflet 
of the inner mitochondrial membrane, but cardiolipin is found in the outer leaflet of 
the inner membrane and the other mitochondrial membrane as well (Figure 1.1) (Saric 
et al., 2016). The first catalytic step of cardiolipin biosynthesis is similar to 
phospholipid synthesis in ER: the conversion of PA. PA is the direct precursor of 
cardiolipin synthesis. In the first reaction, PA is converted into cytidine diphosphate-
diacylglycerol (CDP-DAG) and pyrophosphate, accompanied by the addition of 
cytidine triphosphate (CTP). This reaction is catalysed by CDP-DAG synthase (CDS) 
(Kuchler et al., 1986; Shen et al., 1996). The mitochondria-resident CDS is called 
TAMM41 and initiates the cardiolipin biosynthesis (Kutik et al., 2008; Tamura et al., 
2006; Tamura and Endo, 2013). CDP-DAG and glycerol phosphate (GP) are the 
substrates of the second reaction step catalyzed by the phosphatidylglycerol 
phosphate synthase (PGS1), forming phosphatidylglycerol phosphate (PGP) and 
cytidine monophosphate (CMP) (Chang et al., 1998). PGS1 activity is regulated by 
phosphorylation and may adapt to metabolic changes and mitochondrial biogenesis in 
yeast (Shen et al., 1998; Zhong et al., 2003). PGP is dephophorylated to 
phosphatidylglycerol (PG) by protein-tyrosine phosphatase mitochondrial 1 
(PTPMT1) (Xiao et al., 2011; Zhang et al., 2011). The final step of cardiolipin 
biosynthesis is realized by the cardiolipin synthase (CLS) (Chang et al., 1998; Chen et 
al., 2006; Lu et al., 2006), an integral inner membrane protein, which faces the matrix 
site (Schlame and Halder, 1993). The underlying reaction is  condensation of CDP-
DAG with PG, generating cardiolipin in this step. Interestingly, PGS1 and CLS tend 
to assemble to a hetero-oligomeric complex which is associated to the inner 
mitochondrial membrane by interacting with cardiolipin-binding proteins like the 
MICOS complex, stomatin-like protein 2 and prohibitins (Serricchio et al., 2018).  
 
1.3.2 Cardiolipin remodeling 
 
The CLS reaction forms immature cardiolipin, which requires to be remodeled by an 
exchange of saturated acyl chains with unsaturated acyl chains (Chang et al., 1998; 
Chen et al., 2006; Lu et al., 2006). The deacylation step to form monolysocardiolipin 
(MLCL) is suggested to be performed by calcium-independent phospholipases (iPLA2 
family) (Figure 1.1) (Boynton et al., 2015; Mancuso et al., 2007; Malhotra et al., 
2009; Yoda et al., 2010). Newly synthetized cardiolipin is characterized by an 
asymmetric central carbon atom of the esterified glycerol and contains saturated acyl 
chains of different lengths (Schlame et al., 2005; Schlame and Ren, 2006), whereas 
mature cardiolipin is characterized by symmetric unsaturated acyl chains where all 
acyl chains contain the same length and degree of saturation (Claypool and Koehler, 
2012; Schlame et al., 2005).  
Subsequently, the three different mitochondrial enzymes MLCLAT1, ALCAT1 and 
tafazzin are known to be capable of remodeling immature cardiolipin to the mature 
form.  
 
1.3.3 Tafazzin – the key enzyme in cardiolipin remodeling  
 
Tafazzin, a phospholipid-lysophospholipid transacylase, resides in the inner 
mitochondrial membrane as well as in the inner leaflet of the inner membrane 
(Brandner et al., 2005; Claypool et al., 2006; Gebert et al., 2009; Xu et al., 2015). It 
catalyzes the transfer of an unsaturated acyl chain from phospholipid to 
lysophospholipid (Saric et al., 2016). It is ubiquitously expressed and highly 
conserved across species. Tafazzin is encoded by the TAZ gene (TAZ, G4.5, OMIM 
300394) and is named after an Italian comic character (“Tafazzi”). Deficiency of 
tafazzin causes a decrease in remodeled cardiolipin and an increased 
monolysocardiolipin-to-cardiolipin ratio, which serves as a diagnostic marker for 
Barth syndrome (Houtkooper et al., 2009). Tafazzin activity shows substrate 
specificity towards cardiolipin and phosphatidylcholin. One acyl chain hydrolysed 
from phosphatidylcholine/lecithin (PC) is esterified with monolysocardiolipin by 
tafazzin (Xu et al., 2009). The substrate specificity could be explained by the 
properties of proximal lipid domains where tafazzin is embedded (Schlame et al., 
2012). However, the substrate specificity does not refer to the various acyl chains, 
which can undergo transacylation. Tafazzin can act at the sn-1 and also at sn-2 
positions on acyl chains (Lu et al., 2006; Malhotra et al., 2009). This leads to a high 
variety of cardiolipin species maturated by tafazzin in different organs. Hence, 
tafazzin deficiency like in Barth syndrome causes tissue specific alterations in 
cardiolipin pools (Cole et al., 2016; Dudek et al., 2016; Peyta et al., 2016). 
Furthermore, tafazzin activity requires a lipid environment, which is formed by the 
cochaperone DnaJ Heat Shock Protein Family Member C19 (DNAJC19) and 
cardiolipin-interacting scaffold proteins, called prohibitins (Richter-Dennerlein et al., 
2014).  
 
1.3.4 The role of MLCLAT1 and ALCAT1 in cardiolipin remodeling  
 
The coenzyme A-dependent monolysocardiolipin acyltransferase (MLCLAT1) was 
characterized as a linoleoyl specific transferase (Taylor et al., 2009). MLCLAT1 
resides in the inner leaflet of the inner mitochondrial membrane (Figure 1.1) (Taylor 
et al., 2012). Silencing of MLCLAT1 in Hela cells led to a decreased incorporation of 
linoleic acid into cardiolipin (Taylor et al., 2012), whereas overexpression of 
MLCLAT1 extended reacylation of monolysocardiolipin in Barth Syndrome 
lymphoblasts and led to higher incorporation of linoleic acid into cardiolipin (Mejia et 
al., 2018; Taylor et al., 2012).  
The third known enzyme involved in cardiolipin maturation is acyl-
CoA:lysocardiolipin acyltransferase 1 (ALCAT1). ALCAT1 reside in Mitochondrial 
Associated Membrane of the ER (MAM) where phospholipid traffic between ER and 
mitochondria occurs (Figure 1.1). Contrary to MLCLAT1, ALCAT1 does reveal 
specificity for linoleic acid and incorporates long polyunsaturated acyl chains into 
cardiolipin. ALCAT1 action correlates with oxidative stress and damage because 
cardiolipin species formed by ALCAT1 are more susceptible to peroxidation (Ng et 
al., 2005). Interestingly, observed consequences of ALCAT1 overexpression are 
oxidative stress, mitochondrial fragmentation and mtDNA instability (Li et al., 2012). 
Thus, ALCAT1 shows indications to link cardiolipin remodeling with oxidative stress 
and defects in mitochondrial fusion. 
 
1.3.5 Cardiolipin degradation 
 
The half-life of cardiolipin is relatively long, probably caused by the fact that 
cardiolipin interacts with protein complexes in mitochondrial membranes in 
cardiolipin-rich domains (Xu et al., 2014, 2016). Cardiolipin, which is not bound to 
protein complexes, is more accessible for degradation. The enzymes catalyzing the 
degradation of cardiolipin by deacylation are the members of the phospholipase 
family. One of the candidates is cytosolic PLA2, which degrades specifically mono- 
and dilyso-cardiolipin but not cardiolipin (Buckland et al., 1998). The second 
candidate is phospholipase D, which has been shown to hydrolyse cardiolipin in the 
outer mitochondrial membrane. However, the involvement of phospholipase D in 
cardiplipin turnover needs to be further clarified (Huang et al., 2011). The third 
candidate is phospholipase HSD10, which has been shown to detect oxidized 
cardiolipin and to mediate the cardiolipin degradation. Oxidized cardiolipin perturbes 
mitochondrial functions, indicating that HSD10 plays an important role of 
mitochondrial membrane homeostasis and functions (Boynton et al., 2015).  
 
1.4 Role of cardiolipin in mitochondrial functions 
 
1.4.1 Mitochondria-targeted protein translocation via TOM and TIM23 complex.  
 
Most of the 1500 mitochondrial proteins are nuclear encoded and directed to the 
mitochondrial outer membrane by specific N-terminal presequence and transported to 
their final destination in mitochondrial compartments (Chacinska et al., 2009; 
Morgenstern et al., 2017; Neupert et al., 2007; Voegtle et al., 2017). N-terminal pre-
sequences vary in size but have usually a length of 15-55 amino acids. The special 
property of N-terminal presequence is a positively charged amphipathic α-helix (von 
Heijne, 1986; Roise et al., 1986). The positive charge enables the translocation 
through inner mitochondrial membrane, which is electrostatically propelled by the 
membrane potential. The membrane potential is the driving force of mitochondrial 
protein import (Martin et al., 1991; Shariff et al., 2004; van der Laan et al., 2007). 
The first translocase, which mediates recruiting of presequence-containing proteins is 
the translocase of the outer membrane (TOM). The TOM subunits, TOM20 and 
TOM22 act as receptors and recognize the hydrophobic and polar faces of the 
presequence (Saitoh et al., 2007; Yamano et al., 2008). From this point, proteins can 
be conducted to their final destination in the IMM, OMM, IMS or matrix. The 
structural integrity of the TOM complex and substrate translocation depends on 
remodeled cardiolipin (Figure 1.2).  
Proteins, which are destined to the IMM or matrix are transported via the presequence 
pathway executed by the TIM23 complex (Figure 1.2). The precursor protein arises 
from the TOM22IMS domain and interacts with TIM50IMS with high affinity and can 
be conveyed to the TIM23 channel (Geissler et al., 2002; Schulz et al., 2011; 
Yamamoto et al., 2002). The TIM23 complex is embedded in the inner membrane and 
interacts with the translocase associated motor complex (PAM), facing the matrix side 
(Chacinska et al., 2009; Morgenstern et al., 2017; Neupert et al., 2007; Voegtle et al., 
2017). PAM drives the ATP-dependent precursor protein import and its association to 
TIM23 depends on cardiolipin (Tamura et al., 2006; van der Laan et al., 2007). The 
integrity of the TIM23 complex and the interaction with its receptor constituent 
TIM50 requires cardiolipin (Malhotra et al., 2017; Tamura et al., 2006; van der Laan 
et al., 2007). TIM23 and TIM17 form the channel but just TIM23 interacts with the 
substrate (Martinez-Caballero et al., 2007). Upon the protein import is ensured, N-
terminal presequence-containing precursor proteins are processed via the 
mitochondrial processing peptidase (MPP) (von Heijne et al., 1989).  
 
 
Figure 1.2: Cardiolipin participates and facilitates the key mitochondrial functions (Dudek et 
al., 2018). 
Cardiolipin (red) plays a critical role in maintaining the structural integrity of the respiratory 
chain complexes, protein translocases and MICOS complex. Externalized cardiolipin domains 
act as a platform to initiate mitophagy by recruiting LC3 and apoptosis activation. IM: inner 
membrane, OM: outer membrane, IMS: intermembrane space 
 
1.4.2 Cardiolipin and its involvement in oxidative phosphorylation 
 
The key role of mitochondria is the conversion of chemical energy stored in the form 
of monosaccharides, lipids and amino acids into adenosine triphosphate (ATP) by 
oxidative phosphorylation. Around 95% of whole body ATP is generated by 
mitochondrial respiration (Dudek et al., 2018). The respiratory chain contains four 
protein complexes (CI-IV) and resides in the inner membrane. Reducing equivalents, 
such as NADH and FADH2, generated by catabolic pathways via oxidation of diverse 
carbon sources, transfer electrons on CI and CII, respectively. Those electrons are 
transported from CI and CII to CIII via ubiquinone. The soluble cytochrome c 
transfers electrons from CIII to the CIV for terminal reduction of molecular oxygen. 
The sequential redox reactions of the electron transport chain are exergonic reactions, 
which are coupled with endergonic pumping of protons from the matrix side to the 
intermembrane space via CI, CIII and CIV. The generated electromotive force or 
membrane potential drives the proton import back to the matrix through CV 
accompanied with ATP production. Cardiolipin was shown to be inevitable for 
appropriate activity of respiratory chain complexes (Fiedorczuk et al., 2016; Sharpley 
et al., 2006; Wenz et al., 2009). For instance, one molecule of cardiolipin binds to the 
interaction site of the CIII dimer and is tightly bound even after isolation of CIII 
(Palsdottir et al., 2004). Cardiolipin is also discussed of being involved in proton 
pumping of CIII and CIV. The negative charged “head” of cardiolipin could act as a 
trap for protons and resides close to the ubiquinone reduction site in CIII (Wenz et al., 
2009). Moreover, cardiolipin has one binding site at the discussed proton-conducting 
channel in CIV and could be involved in proton pumping by CIV (Sedlak et al., 1999, 
2006). Cardiolipin maintains the structural integrity of CIV and the CIII dimer, as 
well as the stability of CV oligomers. Cardiolipin binding is required for appropriate 
CV activity and may play a role in proton conduction through CV (Eble et al., 1990; 
Laird et al., 1986). CI and CII also require cardiolipin for their activity and structural 
integrity (Fiedorczuk et al., 2016; Schwall et al., 2012; Sharpley et al., 2006). CII 
levels are shown to be drastically reduced in tafazzin-deficient mouse hearts (Dudek 
et al., 2016).  
CI, CIII and CIV form respiratory chain supercomplexes, which are also referred as  
respirasomes (Lenaz et al., 2009; Milenkovic et al., 2017; Schägger et al., 2002). 
Respirasomes increase the efficiency of the electron transport between redox pairs 
and may decrease the risk of reactive oxygen species (ROS) generation (Dudek et al., 
2016). The lack of remodeled cardiolipin in different tafazzin-deficient models causes 
dissociation of respirasomes (Figure 1.2) (Brandner et al., 2005; Dudek et al., 2013; 
Zhang et al., 2002).  
 
1.4.3 Role of cardiolipin: Mitophagy, apoptosis and morphology maintenance.   
 
In addition to the role on OXPHOS complexes, cardiolipin also affects other 
mitochondrial functions, such as apoptosis, function of metabolite carriers, 
mitochondrial morphology and mitophagy. Starting with mitophagy, mitophagy is a 
specific form of autophagy, which degrades damaged mitochondria by phagophore 
formation (Youle et al., 2012). Recruitment and activation of adapter proteins of the 
autophagic machinery to the outer membrane is facilitated by externalized cardiolipin 
under stress conditions. An increased content of cardiolipin in the outer membrane 
provides a signaling platform for LC3-dependent autophagosomal membrane 
recruitment (Figure 1.2) (Anton et al., 2016; Chu et al., 2013).  
The cardiolipin externalization also plays a role in activation of apoptotic signaling at 
the outer membrane. Caspase-8 can be recruited to the outer membrane, as long as 
cardiolipin is present. The pro-apoptotic member of the Bcl-2 family, Bid interacts 
with cardiolipin of the outer membrane and undergoes caspase-8-dependent 
processing (Figure 2.1). Thus, cardiolipin sustains the homeostasis of apoptotic Bcl-2 
proteins at the outer mitochondrial membrane (Lutter et al., 2000).  
The Mitochondrial contact site and cristae organizing system (MICOS) complex is 
located in the inner membrane and is critical for formation of cristae junctions and 
interaction with the outer membrane (van der Laan et al., 2012). Cardiolipin 
microdomains have been suggested to interact with MICOS components (Figure 1.2) 
(Koob et al, 2015; Weber et al., 2013).  
Alterations in mitochondrial morphology caused by impairments in cardiolipin 
remodeling may lead to pleiotropic and severe physiological phenotypes. The 
consequence of impaired tafazzin function is illustrated by the Barth syndrome and is 
introduced in the following chapter. 
 
1.5 Barth syndrome (BTHS) – Pathophysiology of tafazzin deficiency and 
therapeutic approaches 
 
Barth syndrome (BTHS) is a monogenic and X-linked recessive syndrome, which 
shows an increased degree of infant mortality caused by heart failure or infections. 
The most characteristic symptoms are skeletal myopathy, dilated cardiomyopathy 
(DCM), neutropenia, growth retardation and high levels of 3-methylglutaconic acid in 
urine (Barth et al., 1983; Barth et al., 1999; Clarke et al., 2013; Spencer et al., 2006). 
The genetic origin of BTHS are pathogenic mutations including nonsense, missense, 
frameshift and splicing defects of the cardiolipin remodeling enzyme, TAZ (Bione et 
al., 1996; Ferri et al., 2016; Ronvelia et al., 2012). The X-chromosome-linked 
inheritance reasoned that most of the infant BTHS patients are male individuals, but 
even a female patient was reported (Cosson et al., 2012). The major clinical feature of 
BTHS is a left ventricular non-compaction (LVNC) associated with dilated 
cardiomyopathy (DCM) (Bunse et al., 2003; Merante et al., 1994; Sproudle and 
Kaufmann et al., 2008). Various additional abnormalities as sudden cardiac death, 
ventricular arrhythmia, lethargy, exercise intolerance, hypoglycemia may correlate 
with BTHS disease process (Spencer et al., 2005; 2006).  
BTHS is characterized by reduced mature cardiolipin levels and an enhancement its 
precursor MLCL (Schlame et al., 2003). The MLCL/CL ratio serves to diagnose 
BTHS in patients and BTHS models (Houtkooper et al., 2009). On molecular level, 
different BTHS models show remodeling of respiratory chain complexes. These 
molecular phenotype correlates with decreased mitochondrial membrane potential and 
a reduction in respiratory performance (Dudek et al., 2016; Gonzalvez et al., 2013; 
McKenzie et al., 2006). Deficiency of cardiolipin remodeling causes alterations in 
mitochondrial morphology and altered cristae structure formation (Acehan et al., 
2011). BTHS patient skeletal muscle, heart and liver biopsies show malformed 
mitochondria and fragmented and circular cristae bundles (Barth et al., 1983; Bissler 
et al., 2002; Orstavik et al., 1998).  
Various therapeutic strategies are developed on the basis of these mitochondrial 
features. The aim of all therapeutic approaches is to enrich the pool of cardiolipin in 
relation to its precursor MLCL. First pharmacological inhibition of phospholipase 
activity in BTHS mouse models could rescue reduced cardiolipin levels (Malhotra et 
al., 2009). Second, administration of the precursor linoleic acid rescued sarcomere 
structure in BTHS iPSC-derived cardiomyocytes (Wang et al., 2014) and increased 
cardiolipin levels in BTHS fibroblasts (Valianpour et al., 2002). The overexpression 
of the cardiolipin-synthesizing enzyme MLCLAT1 in BTHS lymphoblasts could 
reduce reactive oxygen (ROS) production and increase cardiolipin level but did not 
revert the respiratory chain remodeling (Mejia et al., 2018). ROS scavenging is an 
additional mechanism to counteract the molecular phenotypes in BTHS. Szeto et al. 
could rescue mitochondrial respiration and cristae morphology (Szeto et al., 2014). 
The Szeto-Schiller peptide (SS-31) interacts with cardiolipin directly, accumulates at 
mitochondrial membranes and scanvenges ROS. Moreover, Wang et al. also used 
MitoTEMPO treatment for ROS scavenging leading to improved sarcomere 
organisation in patient iPSC-derived cardiomyocytes (Wang et al., 2014). 
 
Besides the above addressed roles of cardiolipin, the mitochondrial calcium 
homeostasis is known to depend on sufficient amounts of remodeled cardiolipin. In 
fact, Kamer et al. demonstrated that the Mitochondrial Calcium Uniporter Uptake 1/2 
dimer (MICU1/2), a Mitochondrial Calcium Uniporter (MCU) component, requires 
cardiolipin to be associated with the inner mitochondrial membrane (Kamer et al., 
2017). The following chapter highlights the importance of MCU complex stability 
and constitution in connection to mitochondrial calcium metabolism.  
 
1.6 The role of mitochondria in calcium metabolism 
 
Mitochondrial calcium uptake and release mechanisms play a crucial role in cellular 
calcium homeostasis. Intracellular calcium can be uptaken and stored in the 
mitochondrial matrix preventing excess calcium-stimulated metabolism. Calcium is a 
second messenger of intracellular signal transduction and regulation (Belosludtsev et 
al., 2019; Giorgi et al., 2018; Kwong et al., 2017). Mitochondria are considered as one 
of the organelles, which regulates cellular calcium levels. Mitochondrial activity and 
metabolism are stimulated by calcium. Beside its participation in bioenergetics, 
calcium also plays a role in ROS production (Bertero et al., 2018), cell cycle 
regulation and proliferation (Koval et al., 2019), cell contractility (Eshima et al., 
2018), migration (Paupe et al., 2018; Zheng et al., 2017), and the mitochondrial 
permeability transition pore (mPTP) opening (Penna et al., 2018).  
Calcium homeostasis plays a critical regulatory role in excitation-contraction coupling 
in cardiac and skeletal muscle cells. The calcium-dependent excitation of the muscle 
or cardiac cell facilitates contraction, based on rhythmic cycles of calcium 
release/uptake to the cytosol and subsequent buffering by uptake into organelles, such 
as sarcoplasmic reticulum (SR) and mitochondria. The clearance of cytosolic calcium 
into the SR after an excitation-contraction cycle is performed by the 
sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) in cardiac and 
skeletal muscle cells. Surprisingly, the calcium uptake by mitochondria is lower than 
1% in cardiomyocytes. Conversely, in non-muscle cells, the Mitochondrial Calcium 
Uniporter undertakes a more weighted role in calcium clearance and performs 
intracellular calcium buffering by calcium uptake into the mitochondrial matrix (Bers 
et al., 2002; Fieni et al., 2012).  
 
1.7 The Mitochondrial Calcium Uniporter (MCU) complex 
 
1.7.1 Overview and function 
 
Excess cellular calcium can be uptaken into the mitochondrial matrix by the 
Mitochondrial Calcium Uniporter, which is forced by the electrochemical gradient 
(Baughman et al., 2011; De Stefani et al., 2011). Hence, mitochondria are able to 
buffer excess cellular calcium and stimulate energy catabolism depending on 
metabolic demands. The MCU complex is a calcium-sensing and -transducing 
channel spanning the inner mitochondrial membrane (Figure 1.3) (Baughman et al., 
2011; Kirichok et al., 2004; Tsai et al., 2016; Wang et al., 2019). 
 
  
Figure 1.3: MCU components and their concerted actions to uptake cellular calcium.  
The main constituents of the Mitochondrial Calcium Uniporter complex are the integral 
membrane proteins MCU, EMRE and MCUb forming the calcium-conducting pore in the 
IMM and the IMS-located MCU gatekeepers MICU1 and MICU2. Increased calcium 
transients cause dissociation of the gatekeepers from the pore and enable calcium 
conductance into mitochondrial matrix. MICU1/2 dimer is discussed to be IMM-associated 
via cardiolipin (Kamer et al., 2017).  
 
The uniporter complex consists of six main constituents which are well studied, both 
functionally and structurally (Baradaran et al., 2018; Fan et al., 2018; Yoo et al., 
2018). The core subunit of MCU is the MCU protein. It forms homooligomers, which 
generate the pore-forming subunit within the inner membrane. Cellular calcium is 
sensed in the IMS by calcium-binding EF-hand domains of inner membrane-
associated gatekeeper proteins Mitochondrial Calcium Uptake 1 and 2 (MICU1 and 
MICU2) (Kamer et al., 2017; Liu et al., 2016; Paillard et al., 2018). Calcium binding 
to MICU1/2 exerts conformational changes, which are mediated to the Calcium-
conducting MCU pore through the integral inner membrane protein, Essential MCU 
regulator (EMRE) (Tsai et al., 2016). Two further transmembrane proteins interacting 
with MCU are MCUb and MCUR1, have been shown to exert tissue-specific 
regulatory mechanisms of mitochondrial calcium uptake (Oxenoid et al., 2016; Tsai et 
al., 2016; Wang et al., 2019). 
In the next sections, these six MCU components, their interplay and the orchestrating 
actions in mitochondrial calcium uptake are introduced in more detail.  
 
1.7.2 Mitochondrial Calcium Uniporter (MCU) protein 
 
The Mitochondrial Calcium Uniporter protein (MCU) consists of two transmembrane 
spans permeating the inner mitochondrial membrane and is composed of 350 amino 
acids (39,7 kDa). Structural informations shed light into the architecture of the 
uniporter domains. The structure of the N-terminal domain of MCU (MCU-NTD) was 
determined using nuclear magnetic resonance (NMR), while the coiled coil domain 
(CCD), the transmembrane domain (TMD) and the MCU-NTD were solved by cryo-
electron microscopy (Cryo-EM). Four MCU protein monomers form a tetrameric ion-
selective pore and topology-wise, N- and C-terminus of MCU face the matrix site 
(Baradaran et al., 2018; Fan et al., 2018; Oxenoid et al., 2016; Yoo et al., 2018). The 
TMD contains two transmembrane spans (TM1 and TM2). TM1 interacts directly 
with EMRE and TM2 forms the calcium pore (Fan et al., 2018). The two TM spans of 
MCU are linked by a loop in the intermembrane space and contain the highly 
conserved DXXE motive (X are hydrophobic amino acids). Thereby, aspartate (D) 
and glutamate (E) residues of each MCU monomer form acidic rings and attract 
calcium selectively to the pore (Baughman et al., 2011; de Stefani et al., 2011; 
Oxenoid et al., 2016; Phillips et al., 2019).  
 
1.7.3 Mitochondrial Calcium Uptake 1 protein (MICU1) 
 
Mitochondrial Calcium Uptake 1 protein (MICU1) is a regulatory protein of MCU. 
Three MICU1 isoforms exist in mouse tissues composed of around 477 amino acids, 
having a molecular weight of around 55 kDa. MICU1 expression is ubiquitous, 
whereas the splicing isoform MICU1.1, containing an additional micro-exon between 
exons 5 and 6, is just expressed in brain and skeletal muscle (Vecellio Reane et al., 
2016). MICU1 operates as a molecular gatekeeper of MCU while interacting with the 
DIME sequence of MCU at low calcium currents. This results in an inhibition of 
calcium uptake through the inner mitochondrial membrane (Kamer et al., 2017; Liu et 
al., 2016; Paillard et al., 2018). At higher cellular calcium levels, the MICU1 binding 
site towards MCU can be blocked by chelated calcium. MICU1 is a typical calcium-
binding protein and contains two EF-hand domains. These domains are helix-loop-
helix motifs and are separated by an alpha helix (Kamer et al., 2017). This structural 
constitution enables divalent cation-chelating specificity. The cation-ligand 
interaction of both MICU EF-hands is specific to calcium, but not to manganese 
(Kamer et al., 2018). Kamer et al. revealed in 2018, that manganese can pass the 
MCU pore in a MICU1-KO situation (HEK293T cells), but is incapable to activate 
the conformational change of MICU1 and mediation of MCU pore opening (Kamer et 
al., 2018). The calcium-binding specificity of MICU1 was also shown in the yeast 
model system S. cerevisiae where coexpression of MICU1 and MCU prevents 
manganese forwarding through the inner mitchondrial membrane. Thus, the divalent 
cation-specificity of MICU1 prohibits mitochondrial manganese overload and toxicity 
(Kamer et al., 2018; Wettmarshausen et al., 2018). Lacking MICU1 causes 
mitochondrial calcium overload and can induce myopathic and neurological disorders 
in mice (Liu et al., 2016). In-vivo MICU1 deficiency leads to elevated resting 
mitochondrial calcium levels, decreased ATP production and changes in 
mitochondrial morphology. Similar phenotypes could be observed in MICU1-
deficient patients (Liu et al., 2016). MICU1 does not act alone to mediate calcium-
binding. It is capable to form homodimers and heterodimers with its paralog MICU2 
via disulfide bonds at the C-terminal domains, respectively (Kamer et al., 2017; 
Petrungaro et al., 2015). The disulfide bond is introduced by the oxidoreductase 
Mia40 in the IMS and requires MCU as a platform for MICU dimerization. At low 
calcium levels, MICU-dimers can interact with the pore-forming subunit of MCU.  
Conversely, upon increased calcium concentrations the MICU-dimer dissociates from 
the MCU pore. This finding implicates that MCU complex formation and stability 
take place in a calcium-dependent manner (Petrungaro et al., 2015). The membrane 
association of MICU1/2-dimer could spring from its selective interaction to the 
phospholipid cardiolipin, which was shown with cardiolipin-containing liposomes 
(Figure 1.3) (Kamer et al., 2017). Both, MICU1 and MICU2 have high affinity to 
calcium and more aspects of the cooperative action of uniporter-dependent calcium 
signal transduction in mitochondria are approached in the following chapter. 
 
1.7.4 Mitochondrial calcium uniporter regulator 1 (MCUR1) 
 
Mitochondrial calcium uniporter regulator 1 (MCUR1) occurs in three different 
isoforms in mouse tissues (38 kDa, 31 kDa and 18,6 kDa;). MCUR1 also consists of 
two transmembrane domains similar to MCU, but N- and C-terminus face the IMS 
(Adlakha et al., 2019; Tomar et al., 2016). It is debatable whether it forms a core 
subunit of MCU. Originally, MCUR1 was published by Mallilankaraman et al. in 
2012 as a component of MCU, inevitable for mitochondrial calcium uptake and 
stimulation of mitochondrial bioenergetics (Mallilankaraman et al., 2012). Later on, 
MCUR1 was published by E. Shoubridge lab of not being a MCU component and 
direct regulator, but more of an assembly factor of cytochrome c oxidase assembly 
(CIV) (Paupe et al., 2015). Suppression of MCUR1 in human fibroblasts causes 
depleted mitochondrial membrane potential, a CIV assembly defect and decreased 
mitochondrial calcium uptake (Paupe et al., 2015). Subsequently, it was shown that 
MCUR1 was an interaction partner of the MCU protein and an essential scaffold 
factor. MCUR1 acted as a positive regulator for MCU complex assembly, 
mitochondrial calcium import and stimulation of calcium-dependent mitochondrial 
metabolism (Adlakha et al., 2019; Chaudhuri et al., 2016; Mallilankaraman et al., 
2015; Tomar et al., 2016; Vais et al., 2015). Structurally, MCUR1 contains two 
transmembrane spans and binds directly to the MCU-NTD (Adlakha et al., 2019). 
Depletion of MCUR1 via organ-specific knockout causes impaired calcium uptake 
capacity, reduced ATP production and increased autophagy in cardiomyocytes and 
endothelium cells (Tomar et al., 2016). 
 
1.7.5 Mitochondrial Calcium Uniporter subunit b (MCUb) 
 
Mitochondrial Calcium Uniporter subunit b (MCUb) is a dominant-negative 
constituent of MCU, which acts as a regulator of the Calcium channel activity of 
MCU (Checchetto et al., 2019; Lambert et al., 2019; Raffaello et al., 2013). Murine 
MCUb is composed of 345 amino (39,8 kDa) and similar to MCU, MCUb is a 
putative two-transmembrane-spanned and integral membrane protein. MCUb forms a 
heterooligomeric pore with MCU but does not interact with the gatekeepers MICU1 
and MICU2 (Checchetto et al., 2019; Lambert et al., 2019). As a consequence, MCUb 
alone is not capable to organize a calcium-sensing and -conductive channel through 
the inner mitochondrial membrane (Raffaello et al., 2013). MCUb plays an important 
role for mitochondrial calcium homeostasis because MCU-to-MCUb stoichiometry 
modulates mitochondrial calcium uptake. For instance, overexpression of MCUb in 
adult cardiac myocytes displaces MCU and its interacting gatekeepers MICU1 and 
MICU2 from the inner membrane, with the consequence that the MCU complex size 
is lowered. Hence, cooperative gatekeeper-dependent activation of MCU is 
diminished and the calcium-conductive function is reduced (Lambert et al., 2019). 
Paillard et al. showed that the MCU-to-MCUb ratio varies among different tissues and 
metabolic demands. For instance, the MCU-to-MCUb ratio is relatively high in 
skeletal muscle and reduced in cardiac tissues (Paillard et al., 2017). Thus, MCU-to-
MCUb stoichiometry determines the molecular composition and function of the 
uniporter complex and could be a regulatory mechanism to adapt to different 
physiologic conditions.  
 
1.7.6 EMRE, the Essential MCU Regulator 
 
The Essential Mitochondrial Calcium Uniporter Regulator (EMRE or SMDT1) is a 
TMD-containing inner mitochondrial protein composing of 107 amino acids (11 
kDa). Its N-terminus faces the mitochondrial matrix and the C-terminal domain is 
exposed to the IMS, respectively (Tsai et al., 2016; Wang et al., 2019; Yamamoto et 
al., 2016). Cryo-EM analysis of human MCU-EMRE complex structure demonstrates 
that one EMRE interacts with one MCU subunit. The resulting structure is a MCU-
EMRE tetramer, which turns out as the minimum composition for a calcium-
permeable uniporter. Furthermore, EMRE is needed to initiate the oligomerizaton of 
two MCU-EMRE tetramers to a higher-order MCU complex. The dimerization of two 
MCU-EMRE complexes occurs along the MCU-N-terminal domains (NTDs) in the 
mitochondrial matrix. This MCU-EMRE oligomer is stabilized by the beta-hairpin 
structure of the N-terminal domain of EMRE. This EMRE-dependent oligomerization 
enables the coordination between proximal MCU complexes and functional coupling 
(Wang et al., 2019). Functional MCU in metazoans requires EMRE, whereas some 
primitive eukaryotes do not contain EMRE for appropriate MCU function (Kovacs-
Bogdan et al., 2014; Wang et al., 2019). In response to increased intracellular calcium 
transients, EMRE mediates the calcium-sensing function of MICU1 and MICU2 in 
the IMS with the calcium-conducting function of the MCU pore. This is enabled by 
the interaction of the conserved polyaspartic tail of EMRE (C-terminus) with MICU1 
in the IMS (Tsai et al., 2016). 
In conclusion, EMRE exerts a dual functionality. First, it orchestrates the uniporter 
response to cytosolic calcium signaling via its physical connection to MICU1 and 
second, it stabilizes and activates the MCU pore opening (Tsai et al., 2016). 
 
1.7.7 Proteolytic regulation of MCU composition and activity 
 
MCU assembly, function and turnover were shown to be regulated on transcriptional, 
post-transcriptional and post-translational levels (Nemani et al., 2018). Turnover of 
EMRE is facilitated by the mitochondrial m-AAA metalloproteases AFG3L2 and 
SPG7 (ATPases associated with diverse cellular activities) (König et al., 2016; 
Opalinska et al., 2018). Once assembled in MCU, EMRE degradation is inhibited. 
Loss of AFG3L2 causes inhibition of EMRE degradation and accumulation of 
constitutively active MCU-EMRE sub-complexes (Tsai et al., 2017). Excess MCU-
EMRE subcomplexes could cause calcium leakage into mitochondria, mitochondrial 
permeability transition pore (mPTP) opening and neuronal death in mouse brain 
(König et al., 2016). Moreover, SPG7 KO cells reveal elevated EMRE protein levels 
and alterations in the MCU stoichiometry (Hurst et al., 2019).  
 
1.8 State of art 
 
The aim of the following study has been the characterization of MCU in different 
Barth Syndrome Models under biochemical perspectives. Recent studies about the 
structural integrity of mitochondrial protein complexes showed that respiratory chain 
complexes, translocases, metabolite carriers, MICOS complexes, etc. were depended 
on appropriate action of tafazzin (Dudek et al, 2016; Dudek et al., 2018). The 
dependency of MCU function, complex assembly and stability on tafazzin has never 
been investigated before in mammalian Barth Syndrome models. The importance of 
MCU in the role of mitochondrial and cellular calcium homeostasis in cardiac and 
skeletal muscle function is well studied. Therefore, it was worth checking the 
biochemical properties of MCU in tafazzin lacking models. Two mammalian Barth 
Syndrome models were used in this study. First, WT and TAZ KO MEF cells, a 
murine clonal cell line, and second, different organs from the Rosa shTAZ/BTHS 
mouse. The respiratory chain complexes are remodeled in BTHS cardiomyocytes. 
Steady state levels of complex II are specifically reduced in BTHS mouse hearts 
(Dudek et al., 2016). Putative alterations in the expression levels of MCU constituents 
or complex composition and organization of MCU could affect MCU function and 
mitochondrial calcium homeostasis. These open questions was approached by Blue-
Native PAGE analysis of MCU complex organization in tafazzin-depleted models and 
interaction studies of MCU constituents via coimmunprecipitation.  
The impact of reactive oxygen species (ROS) on MCU activity and complex 
composition is still under debate (Dong et al., 2019). ROS levels are increased in TAZ 
KO MEF cells (Chowdhury et al., 2018) and BTHS cardiomyocytes (Dudek et al., 
2016). Therefore, MCU complexes in TAZ KO MEF mitochondria upon ROS 
scavenging will be investigated. 
The impact of remodeled cardiolipin on translocase stability and activity is not well 
studied. The import and assembly process of MCU components in TAZ KO MEF 
mitochondria will be addressed.  
 






Table 2.1 Chemicals 
Chemicals Supplier 
[35S]-L-methionine Hartmann Analytic (Braunschweig, 
Germany) 
2-Mercaptoethanol Sigma-Aldrich 
4- Nitro blue tetrazolium chloride Roth 
6-Aminocaproic acid Sigma-Aldrich 
Acetic acid Roth 
Acetone Roth 
Acrylamide/bisacrylamide (37.5:1) solution Roth 
Acrylamide, 2x crystallized Roth 
Agarose NEEO ultra-quality Roth 
Ampicillin AppliChem 
Anti-FLAG M2 Affinity Gel Sigma-Aldrich 
Antimycin A Sigma-Aldrich 
ATP (Adenosine-5´-triphosphate) Roche 
Bis-Tris Buffer grade AppliChem 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol Blue Merck 
Cardiolipin Avanti 
Chloroform Roth 
cOmplete,  EDTA-free  protease  inhibitor 
Tablet Roche 
Coomassie Brilliant Blue G-250 Serva 
Coomassie Brilliant Blue R-250 Serva 
Copper(II)sulfate pentahydrate Merck 
Creatine kinase Roche 
Creatine phosphate Roche 
Coomassie Brilliant Blue R-250 Serva 
Cycloheximide Applichem 
Cytochrome c Calbiochem 
Diaminobenzidine Sigma-Aldrich 
Digitonin Calbiochem 
Dipotassium phosphate Roth 
Disodium phosphate Roth 




Ethidium Bromide (0.025%) Roth 
Fetal Bovine Serum Biochrom 
Glucose Roth 




Hydrochloric acid, 37% Roth 
Hydrogen peroxide Sigma-Aldrich 
IgG from human serum Sigma-Aldrich 
IgG protein standard BioRad 
Imidazole Roth 
Magnesium acetate Merck 
Magnesium chloride Merck 










o-phosphoric acid Merck 
Opti-Mem Life Technologies 
OrangeG Sigma-Aldrich 
Oxaloacetic acid Sigma-Aldrich 







Potassium chloride Roth 
Potassium cyanide Sigma-Aldrich 
Potassium hydrogen phosphate Merck 
Potassium dihydrogen phosphate Roth 
Protein-A sepharose GE Healthcare 
Proteinase K Roche 
PVDF membrane (Immobilon-P) Merck 
Roti-Quant® reagent Roth 
SDS (sodium dodecyl sulfate) Serva 
SDS marker broad range Biorad 
SDS-PAGE protein standard Serva 
Sodium chloride Roth 
Sodium hydroxide Roth 
Sodium pyruvate Sigma-Aldrich 
Sodium succinate Sigma-Aldrich 
Sucrose Roth 
Tetramethylethylenediamine (TEMED) Roth 
Tetracycline hydrochloride Sigma-Aldrich 
Trehalose Roth 
Tricine Roth 
Trichloroacetic acid Roth 
Triethylamine Roth 







2.1.2 Buffers and solutions 
 
Table 2.2 Buffers and solutions 
35S-labeling medium DMEM (Dulbecco’s Modified Eagle Medium) 
with  or  without  fetal  calf  serum,  without 
sodium pyruvate, L-Glutamine, L-Methionine 
and L-Cysteine (filtered) 
 
AVO mix 0.8 mM antimycin, 0.1mM valinomycin, 2mM 
oligomycin in ethanol 
Blotting buffer 20mM Tris, 150mM glycine, 0.02% SDS, 20% 
methanol 
BN anode buffer 50mM Bis-Tris/HCl pH 7.0 
BN cathode buffer 50mM Tricine, pH 7.0, 15mM Bis-Tris, with or 
without 0.02% Coomassie Brilliant Blue G-250 
BN gel buffer 66.67mM  6 -aminocaproic  acid,  50mM  Bis-
Tris/HCl pH 7.0 
BN sample loading buffer 0.5% Coomassie Brilliant Blue G-250, 50mM 6- 
aminocaproic acid, 10mM Bis-Tris, pH 7.0 
BN solubilization buffer 1% Digitonin, 20mM Tris/HCl pH 7.4, 0.1mM 
EDTA, pH 8, 50mM NaCl, 10% Glycerol, 1mM 
PMSF 
Cell culture medium DMEM (Dulbecco’s Modified Eagle Medium) 
supplemented with 10% (v/v) fetal calf serum 
(FCS), 1mM sodium pyruvate, 2 mM L- 
Glutamine, and with or without penicillin 
streptomycin (filtered) 
Coomassie staining solution 2.5g/L  Coomassie  Brilliant  Blue  R-250,  40% 
ethanol, 10% acetic acid 
Coomassie destaining solution 40% ethanol, 10% acetic acid 
Hypertonic buffer 1.25mM   Sucrose,   10mM   MOPS,     pH   7.2 
(filtered) 
Hypotonic buffer 100mM Sucrose, 10mM MOPS, pH 7.2, 1mM 
Import buffer 250mM Sucrose, 5mM magnesium acetate, 
80mM potassium acetate, 5mM methionine, 
10mM sodium succinate, 5mM ATP, 20mM 
Hepes, pH 7.4 
Isolation buffer for mitochondria 
isolation from mouse tissues 
20 mM Hepes pH 7,6 (0,95g/200 mL) 
220 mM Mannitol 88,02g/200 mL) 
1 mM EDTA (74 mg/200 mL) 
70 mM Mannitol (4,79 g/200 mL) 
In 50 mL add 1 mL Roche protease inhibitor 
Isolation buffer 75mM Mannitol, 225mM Sucrose, 10mM 
MOPS, pH 7.2, 1mM EGTA (filtered) 
Krebs-Ringer solution 135 mM NaCl, 5 mM KCl, MgSO4 1 mM, 
K2HPO4 0,4 mM, Glucose 5,5 mM, HEPES 20 
mM, pH 7,4, 1 mM CaCl2 
Lysogeny broth (LB medium) 1% NaCl, 0,5% yeast extract, 1% tryptone 
Potassium phosphate buffer, pH 7.4 19% KH2PO4, 81%K2HPO4 
PBS (phosphate-buffered saline) 
Resolving gel (BN-PAGE) 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 
1.8mM KH2PO4 with or without 1mM EDTA 
(autoclaved) 
Resolving gel (SDS-PAGE) 4-16.5% acrylamide/bisacrylamide (49.5%/3%), 
1x BN gel buffer (see above), 2-30% Glycerol 
Resolving gel (Tricine-SDS-PAGE) 10-18% acrylamide/bisacrylamide (49.5%/3%), 
1x Tris-Tricine gel buffer (see below), 0-13% 
glycerol 
ROS assay buffer 20 mM Tris, 150 mM NaCl, 0.1% Triton, 3 mM 
ADP, 10 mM Succinate, pH 7.4 
Stacking gel (BN-PAGE) 2% acrylamide/bisacrylamide (49.5%/3%), 1x 
BN gel buffer 
Stacking gel (SDS-PAGE) 5% acrylamide/bisacrylamide (37.5/1), 80mM 
Tris-HCl pH 6.8, 0.1% SDS 
Stacking gel (Tricine-SDS-PAGE) 4% acrylamide/bisacrylamide (49.5%/3%), 1x 
Tris-Tricine gel buffer 
SDS running buffer 25mM Tris, 192mM glycine, 0.1% SDS 
SDS sample buffer 10% glycerol, 2% SDS, 0.01% bromophenol 
blue, 60mM Tris/HCl pH 6.8, 1% beta-
mercaptoethanol 
SEM buffer 250mM sucrose, 1mM EDTA, 10mM EDTA, 
pH 7.2 
TAE buffer 40mM Tris/acetate pH 8.0, 2mM EDTA 
TBS (Tris-buffered saline) 20mM Tris/HCl, pH 7.5, 125mM NaCl 
TBS-T 
20mM Tris/HCl, pH 7.5, 125mM NaCl, 0.1% 
Tween-20 
THE-buffer 
10mM Hepes, 10mM KCl, 300mM trehalose 
with or without 0.1% BSA (filtered) 
Tris-Tricine anode buffer 0.2M Tris, pH 8.9 
Tris-Tricine cathode buffer 0.1M Tricine, 0.1M Tris, 0.1% SDS, pH 8.25 
Tris-Tricine gel buffer 1M Tris, 0.1% SDS (autoclaved), pH 8.45 
 
 
2.1.3 Kits and disposables 
 
Table 2.3 Kits and disposables 
Product Supplier 
Blotting paper Heinemann Labortechnik 
Complex  IV  Human  Specific  Activity  
Microplate Assay Kit 
abcam 
FastDigest restriction enzymes Thermo Scientific 
Flexi® Rabbit Reticulocyte Lysate System Promega 
GeneRuler DNA Ladder Mix Fermentas 
KOD Hot Start DNA Polymerase Novagen 
Microtube 1.5mL and 2mL Sarstedt 
MITOSOXTMRedmitochondrialsuperoxide 
indicator for live-cell imaging 
Invitrogen 
Pierce® ECL Western Blotting Detection 
Reagent 
Thermo Scientific 
Pipette tips 10, 200µL, 1mL Sarstedt 
Precision Blue ProteinTM  Standards All Blue 
(10  – 
250kDa) 
BioRad 
Rapid DNA Ligation Kit Thermo Scientific 
SP6 mMESSAGE mMACHINE® Kit Ambion 




Unstained   SDS-PAGE   Protein   marker   
(6.5   – 
200kDa) 
Serva 
Wizard® Plus SV Gel and PCR DNA 













2.1.4 Instruments and equipment 
 
Table 2.4 Instruments and equipment 
Instrument Supplier 
5415 R (centrifuge) Eppendorf 
5417 R (centrifuge) Eppendorf 
5424 (centrifuge) Eppendorf 
5804 R (centrifuge) Eppendorf 
Cary 50 Bio UV-Visible Spectrophotometer Varian 
CountessTM automated cell counter Thermo Scientific 
Curix 60 (developing machine) AGFA 
Dounce homogenizer (glass-glass, BBI-8540705) Sartorius 
EPS 601 power supply GE Healthcare 
FACS CantoTM II BD Biosciences 
Fluorescence scanner FLAG-9000 Fujifilm 
GeneAmp® PCR System 9700 (thermo cycler) Applied Biosystems 
GD-5040 vacuum gel dryer Scie-Plas 
Heraeus®  Biofuge pico (centrifuge) Thermo Scientific 
Heraeus®  Hera cell 150 (incubator) Thermo Scientific 
Heraeus®  Hera safe (sterile hood) Thermo Scientific 
Hoefer SE600 Ruby Blue native system GE Healthcare 
HPTLC Silicagel60 F254 glass plates Merck 
NanoVueTM  Spectrophotometer GE Healthcare 
Potter S (Dounce homogenizer) Sartorius 
Semi Dry Blotting Chamber PEQLAB Biotechnologie 
StormTM 820 Phosphoimager GE Healthcare 
Storage Phosphor screen GE Healthcare 
Thermomixer comfort Eppendorf 
Typhoon FLA 9500 Phosphoimager GE Healthcare 
Universal 320 (centrifuge) Hettich 
Vaccubrand® 2C Gel pump Scie-Plas 





Table 2.5 Software 
Software Producer 
Microsoft Office Microsoft 
Adobe Illustrator CS6 Adobe 
Adobe Photoshop CS6 Adobe 
Genious Pro Biomatters Ltd. 
FiJi/ImageJ OpenSource 
ImageQuant TL GE Healthcare 





Table 2.6 Primary antibodies 
Antibody Source 
Rabbit polyclonal ANTI-RIESKE Home-made 
Rabbit polyclonal ANTI-COX1 Home-made 
Rabbit polyclonal ANTI-SDHA Home-made 
Rabbit polyclonal ANTI-ATP5B Home-made 
Rabbit polyclonal ANTI-LONP1 Home-made 
Rabbit polyclonal ANTI-TIM23 Home-made 
Rabbit polyclonal ANTI-TIM21 Home-made 
Rabbit polyclonal ANTI-TIM22 Home-made 
Rabbit polyclonal ANTI-COX6a Home-made 
Rabbit polyclonal ANTI-AGK Home-made 
Rabbit polyclonal ANTI-NDUFB8 Home-made 
Rabbit polyclonal ANTI-TIM50 Home-made 
Rabbit polyclonal ANTI-TOM70 Home-made 
Rabbit polyclonal ANTI-TOM40 Home-made 
Rabbit polyclonal ANTI-TOM20 Home-made 
Rabbit polyclonal ANTI-COX5a Home-made 
Rabbit polyclonal ANTI-COX4I1 Home-made 
Rabbit polyclonal ANTI-VDAC3 Home-made 
Rabbit polyclonal ANTI-TIM21 Home-made 
Rabbit polyclonal ANTI-COX2 Home-made 
Rabbit polyclonal ANTI-TACO1 Home-made 
Rabbit polyclonal ANTI-TIM44 Abcam, ab168649 
Rabbit polyclonal EMRE Santa Cruz, sc-86337 
Rabbit polyclonal MCU Sigma, HPA016480 
Rabbit monoclonal MICU1 Cell Signaling, 12524 
Rabbit polyclonal MCUR1 Proteintech, 24948-1 
Rabbit polyclonal MCUb Sigma, HPA048776 
Rabbit polyclonal COX4I2 Proteintech, 11463-1 
Rabbit polyclonal CRLS1 Abcam, ab156882 
Rabbit polyclonal MICU2 Abcam, ab101465 
 
Table 2.7 Secondary antibodies 
Antibody Source 
Goat anti-rabbit IR880 LI-COR, Lincoln, NE, USA 
Goat anti-mouse IR880 LI-COR, Lincoln, NE, USA 
Goat anti-mouse HRP Dianova, Hamburg, Germany 
Goat anti-rabbit HRP Dianova, Hamburg, Germany 
 
 
2.1.7 Oligonucleotides and plasmids 
 
















Table 2.10 Plasmids  
Plasmid name Purpose Features Marker Reference 












pcDNA5/FRT/TO Genomic  
integration  
























































OTC Vector for in vitro 
Transcription and 
Translation of OTC 
SP6, T7 
promoter 










Amp Jan Dudek 
pGEM4Z-EMRE 
(human) 










2.2.1 Mammalian cell culture techniques 
 
2.2.1.1 Cultivation of Mouse Embryonic Fibroblasts (MEF cells) 
 
H-ras transformed and SV40-large T immortalized Mouse Embryonic Fibroblasts 
(MEF cells) were cultured in 10% fetal bovine serum (FBS) (GIBCO, Invitrogen) 
containing DMEM (Dulbecco’s Modified Eagle Medium) at 5% CO2 humidified 
atmosphere and 37 °C. For cell passaging, MEF cells were washed once with PBS 
and detached from flask surface with Trypsin/EDTA for 3 min. Trypsin was 
inactivated by adding an appropiate amount of FBS-containing DMEM. Cells were 
centrifuged at 1500 rpm for 5 min. at RT. Subsequently, the cell pellet was 
resuspended in 5-10 ml DMEM and 0,5-1 ml cell suspension were seeded to a new 
flask for maintenance.  
 
2.2.1.2 Silencing of mRNA/protein expression levels via RNAi  
 
MEF cells were seeded and grown in DMEM w/o antibiotics until a confluency of 50-
80 % to ensure a proliferating metabolic state. Cells were harvested and counted by 
Neubauer counting chamber. In between, siRNA (Eurogentec)/Lipofectamine 
(RNAiMax)/Optimem mix was prepared in a disposable culture tube. The final 
concentration of siRNA in culture was 50 nM. Therefore, the cells-to-siRNA ratio 
was prepared as follows: 600.000 cells/27 µl siRNA (20 µM)/18 µl 
Lipofectamine/2,24 ml Optimem. The siRNA/Lipofectamine/Optimem mix was 
mixed by pipetting for 10 times preventing bubbles and vortexing and incubated for 
20 min. at RT. The desired number of MEF cells was added to the 
siRNA/Lipofectamine/Optimem mix and completed with DMEM ad 10 ml. Non-
target siRNA and Targetgen siRNA were seeded to 10 cm plates and cultivated at 5 % 
humidified atmosphere and 37 °C for 3 days.  
 
2.2.1.3 Electroporation of plasmid DNA  
 
Plasmid DNA was transiently transfected to cultured MEF cells by electroporation via 
the NEON transfection system (Invitrogen).  MEF cells required to be splitted one 
day in advance to obtain a cell confluency of 60-80%. Cell detachment and harvesting 
was performed as described in 2.2.1.1. The cell number was determined by Neubauer 
counting chamber. 100.000 cells each were aliquoted to 1,5 ml Eppendorf tubes and 
centrifuged at 2000 rpm, 5 min. Afterwards, cells were washed with PBS and 
centrifuged again. The cell pellet is resuspended in R-buffer from the kit and mixed 
with 1 µg plasmid DNA via pipetting up and down mildly. The cell/plasmid DNA 
mix was then electroporated at these conditions: Program HEKB, Voltage 1150, 
Width 20, pulses 2. Electroporated cells were transferred immediately to prepared, 
warm DMEM medium and seeded in appropiate plates for growing. After 2-3 days 
cells were harvested at a confluency of 80-100%.  
	
2.2.1.4 Control and patient-derived inducent pluripotent stem cell 
cardiomyocytes (iPSC-CM) 
 
Control and patient-derived inducent pluripotent stem cell cardiomyocytes (iPSC-
CMs) were generated and characterized as already described (Dudek et al., 2016). The 
iPSC-CM line TAZ 10 was obtained from a BTHS patient, which carried the TAZ 
mutation c.590 G > T (Dudek et al., 2013). The iPSC-CMs were seeded as adherent 
cultures on Geltrex-coated cell culture plates in E8 Essential medium (Life 
Technologies). iPSCs were differentiated to cardiomyocytes within 30 days via 
modulation of canonical Wnt pathway. Addition of 4 mM lactate in substitution of 
glucose for 6 days caused enrichment of cardiomyocytes (Tohyama et al., 2013).  
iPSC-CMs were cultivated in RPMI 1640 medium (HEPES/GlutaMax, Life 
technologies) supplemented with insulin and B27 (Life technologies). iPSC-CMs 
were detached from dishes by 0,25 % trypsin-EDTA (Life technologeis) and 
reseeding.  
	
2.2.2 Mouse model 
 
2.2.2.1 Maintenance of mice  
 
The study and the maintenance of all mice were conducted in accordance with the 
German Animal Welfare Act and confirmed by the Landesamt für Verbraucherschutz 
und Lebensmittelsicherheit Niedersachsen, Germany (AZ: 33.9-42502-04-15/1991). 
WT C57BL/6J and transgenic mice (ROSA26H1/tetO-shRNA:TAZ) were feeded by 
standard rodent chow and administration of doxycyline (625 mg/kg) (Acehan et al., 
2011; Soustek et al., 2011). Doxycycline treatment was annuled during mating to 
prevent infertility oft he males. Females were only treated with doxycyline until one 
week before mating. Doxycycline treatment was proceeded when copulatory plugs 
were noticed. The pups were treated for 8 weeks continuously. Assessment oft he 
genotype was performed using PCR (Acehan et al., 2011).  
 
2.2.2.2 Mitochondria isolation from mouse tissues via differential centrifugation 
 
Mouse tissues (heart, skeletal muscle, brain, liver) were dissected and cut in small 
pieces by dissection scissors. The minced organ pieces were resuspended with 2 ml of 
mouse tissue isolation buffer (Table 2.2) and dounced with 20 gentle handstrokes in a 
glass-glass Dounce homogenizer (Sartorius). The potter was kept on ice. The 
suspension was centrifuged at 1000g, 10 min., 4 °C., supernatant was kept and again 
centrifuged to discard remnant insolved material. Transfer of suspension was 
performed on a mild way with plastic Pasteur pipettes or decanting. Cleared 
supernatant was spinned down at 10.000g, 10 min., 4 °C to obtain pelleted 
mitochondrial fraction. Mitochondrial pellet was resuspendend with 50-200 µl mouse 
tissue isolation buffer receiving an end concentration of around 10 µg/µl.  
 
2.2.3 Molecular biology 
 
2.2.3.1 Transformation of plasmid into E.coli 
 
The ligated plasmid of previous cloning was transformed into bacteria to amplify the 
yield. Therefore, rubidium-competent bacteria (Escherichia coli XL-1 blue) were 
thawed on ice. 50 µl of bacteria were mixed with 5 µl plasmid and incubated on ice 
for 15 min. After that, the plasmid/bacteria mix was heatshocked at 42 °C for 2 min. 
Mix was put on ice for 2 min and 1 ml LB medium (lysogeny broth) was added and 
incubated at 37 °C for 1 hour. Bacteria were centrifuged at full speed for 1 min and 
pellet was resuspended in 100 µl LB medium. The resuspension was plated on a 
Ampicillin (0,1 g/l)-resistent LB agar (15 g/ml agar) and incubated over night at 37 
°C. On the next day clones were picked by a yellow pipette tip and inoculated into 5 
ml LB medium (Ampicillin-resistent). Bacteria grew over night at 37 °C under 
constant shaking and next day the bacteria suspension was either reinoculated into 
100 ml LB medium to reach higher yield of plasmid (Maxiprep) or plasmid was 
purified on a lower scale (Miniprep) to examine the insert sequence by sequencing or 
plasmid digestion.  
 
2.2.3.2 Plasmid DNA isolation from E.coli 
 
Plasmid isolation on a larger scale (Maxiprep) was used to reach plasmid 
concentrations of 5 µg/µl, which was nessecary for electroporation of plasmids to 
cells (2.2.1.3). The optical density (OD) of a 100 ml LB medium containing E. coli 
bacteria was measured. The bacteria suspension should have a OD of 2,3 – 2,6, 
otherwise the suspension was diluted with LB medium. Culture was pelleted in 50 ml 
falcon tubes at 3400g for 10 min and the supernatant was discarded. The Maxiprep 
was perfromed with the ZymoPURE Plasmid Maxiprep kit. Bacteria pellet was 
resuspended with 14 ml of ZymoPURE P1 resuspension and lysing buffer and mixing 
by inverting six times. Then, 14 ml of ZymoPure P2 buffer were added, gently mixed 
but thoroughly by inversion. ZymoPure P3 neutralizaiton buffer was added (14 ml) 
and mixed by inversion. It took 6-8 min to reach precipitation of the suspension. The 
suspension was transferred to a 50 ml syringe. The suspension was pushed through a 
filter by a plunger into a falcon tube to clear the solution from precipitations. 14mL 
ZymoPURE Binding Buffer was added to the cleared lysate and mixed by inverting 
several times. The ZymoSpin Column reservoir was assembled onto a vacuum 
manifold. The lysate was added to the ZymoSpin Column reservoir and vacuum was 
turned on causing, that all of liquid has passed completely through the column. The 
upper part of the reservoir was removed from the column assembly and 5 ml of 
ZymoPURE Wash 1 buffer was added. Vacuum was kept on and washing buffer 
passed through the column. The washing step was repeated twice with 5 ml of 
ZymoPURE Wash 2 buffer. Column was transfered to a table-top centrifuge. Residual 
washing buffer was removed by centrifugation (10000g for 1 min). Column was 
transfered to a clean 1,5 ml tube and kept for 2 min at RT. 250 µl pre-warmed 
deionizied water were added slowly to the column. Column was incubated for 2 min 
at RT and centrifuged at 10000g for 1 min. The plasmid concentration was 
determined and the concentration was adjusted to 5 µg/µl. If the concentration was 
too low, the plasmid solution was subjected to a SpeedVac to evaporate water and 
concentrate the plasmid.  
Plasmid isolations from E. coli were performed on a smaller scale (Miniprep) as well. 
Therefore, PureYield Plasmid Miniprep System kit by Promega was used and was 
followed by manufacturers instructions.  
 
2.2.3.3 Polymerase chain reaction (PCR) 
 
DNA fragments from purified plasmids were amplified by the KOD Hot Start DNA 
Polymerase kit. Manufacturers instructions were followed. The reaction mixture had a 
total volume of 50 µl and contained 1x KOD reaction buffer, 0.3µM forward and 
reverse primer pairs, 0.2mM dNTPs, plasmid or cDNA (template), 1mM MgSO4, 
0.2mM dNTPs, and 1 unit of KOD DNA polymerase. The PCR started with a heating 
step (2 min at 95°C) and 35 cycles followed. The heating step of the PCR cycle was 
95°C for 10 sec. The time and temperature of the annealing step was depending on the 
primer pairs (10-15 sec. at 52°-55°C). Elongation step took 20-100 sec. at 70°C and 
was depending on the PCR product size.  
 
2.2.3.4 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was performed to confirm the presence of a specific PCR 
product and to examine the correct size after the PCR. The separation of DNA was 
conducted in a 1% agarose gel. Therefore, dry agarose was dissolved in 1x TAE 
buffer (Table 2.2). The agarose solution was heated in a microwave and colled under 
gentle shaking. One drop of DNA intercalating ethidium bromide was added and 
solution was casted in the gel apparature. After solidification of the agarose gel 5µL 
of the PCR reaction were mixed with 5µL of 2x loading dye. The samples and the 
ladder mix (Gene Ruler) were loaded into the slots of the gel and run for 20 min at 
120 V. UV-light visualized the DNA fragments. 
 
2.2.3.5 Purification of PCR products 
 
The Wizard® Plus SV Gel and PCR DNA Purification kit was used to purify PCR 
products according to manufacturer’s instructions. PCR products were either 
dissolved from gel slices after agarose gel electrophoresis or purification was 
performed with the PCR solution directly after amplification. Following 
electrophoresis, DNA band of interest was excised from gel and gel slice was placed 
in a 1,5 ml microcentrifuge tube. 10 µl of membrane binding buffer per 10 mg of gel 
slice were added. The solution was incubated at 50-65 °C under harsh agitation until 
the gel slice was completely dissolved. For the second variant, equal amount of 
membrane binding buffer was added to the 50 µl of PCR product. The SV 
Minicolumn was inserted into the Collection Tube. Prepared PCR product or 
dissolved gel mixture were transferred to the Minicolumn assembly and incubated for 
1 min at RT. Minicolumn was centrifuged at 16000 g for 1 min and flowthrough was 
discarded. Minicolumn was inserted into the Collection Tube. To wash the column, 
700 µl Membrane Wash Solution were added and centrifuged at 16000 g for 1 min. 
This washing step was repeated with 500 µl Membrane Wash Solution. Minicolumn 
was centrifuged at 16000 g for 5 min. The Collection Tube was emptied and the 
column assembly was centrifuged for 1 min with the microcentrifuge lid open to 
allow evaporation of remnant ethanol. The Minicolumn was transferred to a clean 1,5 
ml microcentrigue tube. 50 µl of nuclease-free water were added to the Minicolumn 
and incubated for 1 min at RT. To elute the DNA from the column, it was centrifuged 
at 16000g for 1 min at RT. The purified DNA was quantified by a NanoVueTM 




Purified PCR products were inserted into plasmids. Both, PCR product and the 
plasmid underwent restriction digestion using Fast Digest restriction enzymes 
(Thermo Scientific). The total volume of the digestion of the PCR product was 30 µl. 
1 µl of both restriction enzymes, 5 ml of nuclease-free water, 3 µl of 10x Fast Digest 
buffer and 20 µl of the PCR reaction were mixed and incubated for 30 min at 37 °C 
under mild agitation. 1 µl plasmid vector was mixed with 1 µl of both restriction 
enzymes, 2 µl of 10x Fast Digest buffer and 15 ml nuclease-free water. Plasmid and 
PCR product were digested for 1-2 hours at 37 °C. The plasmid was 
dephosphorylated by adding alkaline phosphatase (1 µl) and incubation for 45 min at 
37 °C. Both samples were purified by PCR purification kit. Ligation of plasmid and 
PCR product was performed using the Rapid DNA Ligation Kit (Thermo Scientific). 
2 µl of digested plasmid, 1µL T4 DNA ligase, 60ng of digested PCR product and 1x 
ligation buffer were mixed to a total volume of 20µl. The ligation mix was incubated 
for 30 min at 22 °C at mild agitation. The plasmid was transformed into XL Blue E. 
coli bacteria (2.2.3.1) and isolated from colonies (2.2.3.2). Constructs were tested by 
sequencing (SEQLAB, Göttingen, Germany) and restriction digestion followed by 
separation via agarose gel electrophoresis (2.2.3.4) 
 
2.2.3.7 In vitro transcription 
 
The SP6 mMESSAGE mMACHINE® Kit by Ambion was used to perform in vitro 
transcription from purified PCR products, which contained a SP6 promotor. Due to 
manufacturer’s instructions, 2 µl of 10x NTP/CAP, 10 µl of 2x reaction buffer, 6 µl of 
purified PCR product (independently from the concentration) and 2µL of enzyme mix 
were mixed to a total volume of 20 µl. The transcription mix was incubated for 90 
min at 37 °C under mild agitation. 30µL of lithium chloride (7.5M and 50mM EDTA) 
were added to precipitate the synthesized RNA over night at -20 °C. Samples were 
centrifuged at 20000 g for 15 min and supernatants were removed. The pellet was 
resuspended with 70 % ethanol and centrifuged at 20000 g for 15 min. Supernatant 
was discarded carefully and residual ethanol was evaporated at RT. The pellet was 
resuspended in nuclease-free water and incubated on ice for 30 min. The volumes 
were depending on the size of the pellet (10 – 40 µl). Synthezised RNA was 
quantified by a NanoVueTM spectrophotometer. RNA was stored at -80°C. 
 
2.2.3.8 In vitro translation 
 
The Flexi® Rabbit Reticulocyte Lysate kit (Promega) was used to perform in vitro 
translation of mitochondrial precursor proteins from mRNA. Therefore, 33 µl of 
Flexi® Rabbit Reticulocyte Lysate were mixed with 1 µg of mRNA in a final volume 
of 50 µl. Due to manufacturer’s instructions, 1µL of amino acid mixture without 
methionine (1mM), magnesium acetate (0-2mM), potassium chloride (70-120mM) 
and 35S-methionine were added and incubated for 90 min at 30 °C. After that, 5 µl of 
non-radioactive methionine were added for 1 min. Sucrose was added for an 
additional minute. The protein lysate was kept on ice for an in-vitro precursor import 
into freshly purified mitochondria (2.2.5.1).  
The second approach to synthesize mitochondrial precursor proteins for in vitro 
import reactions was a combined transcription and translation by the TNT® Quick 
coupled Transcription/Translation kit (Promega). Transcription and translation were 
performed directly from the plasmid (pTNT backbone), which contained the open 
reading frame of the precursor protein. 200 ng of the plasmid were mixed with 40 µl 
of the TNT® Quick Master Mix and 50µCi 35S-methionine for 90 min at 30 °C. 5 µl 
of non-radioactive methionine were added for 1 min. Sucrose was added for an 
additional minute. The protein lysate was kept on ice for an in-vitro precursor import 
into freshly purified mitochondria (2.2.5.1).  
 
2.2.4 Protein separation and protein complex analysis 
 
2.2.4.1 Determination of protein concentration via Bradford assay  
 
Protein concentrations of mitochondrial or cellular fractions were determined via 
Bradford assay (Roti®-Quant (Serva)) to obtain equal protein amount adjustments in 
subsequent experiments. 
The protein amount in the sample was calculated by linear regression curve of the 
bovine immunoglobulin standard (IgG standard). The IgG standard solution was 
diluted to 0, 7.5, 15, 30 and 60 µg/µl and mitochondrial/cellular suspensions were 
diluted 1/10. Water was added to obtain a final volume of 86 µL. 1/5 diluted Roti®-
Quant reagent was appended to all solutions and the optical density was measured at 
595 nm (Cary 50 Bio UV-visible spectrophotometer (Varian)). 
 
2.2.4.2 Protein separation via SDS-PAGE analysis 
 
Protein samples were denatured by SDS/Laemmli sample buffer (Table 2.2) at 95 °C, 
5 min. under reducing conditions (w/ DTT) or at 37 °C, 15 min. under non-reducing 
conditions (w/o DTT).  Denatured protein samples were applied to 10-16,5% SDS-
PAGE (Laemmli, 1970) to separate proteins electrophoretically according to their 
molecular weight.  
The 10-16,5% running gel was prepared by 386mM Tris/HCl pH 8.8, 0.1% SDS, 
30%/0.8% acrylamide/bisacrylamide solution (Roth). The stacking gel was prepared 
by 80mM Tris/HCl, pH 6.8 and 0.1% SDS, 4% acrylamide. APS and TEMED 
initiated and catalyzed acrylamide polymerization. Denatured protein samples were 
loaded to polymerized stacking gel wells and were electrophoretically separated at 
250V, 25mA/gel, 2-3 hours in 1x SDS running buffer (GE Healthcare, 




Tris-Tricine polyacrylamide gradient gels (10-18%) were utilized to improve the 
separation of the whole molecular weight range and to increase the resolution of small 
proteins with a size lower than 15 kDa. 10-18% Tris-Tricine-SDS-PAGE resolving 
gels was prepared by 1M Tris/HCl pH 8.45, 49.5%/3% acrylamide/bis-acrylamide, 
0.1% SDS and 13% glycerol (for 18%). 10% and 18% solutions were casted with a 
homemade gradient mixer. The 4% stacking gel comprised 1M Tris/HCl, 4% 
acrylamide, pH 8.45 and 0.1% SDS and was casted on top of the resolving gradient 
gel. APS and TEMED initiated and catalyzed acrylamide polymerization. Denatured 
protein samples were loaded to polymerized stacking gel wells and were 
electrophoretically separated at 80V, 25mA/gel, overnight in Tris-Tricine cathode and 
anode buffer (Table 2.2) (GE Healthcare, Electrophoresis Power Supply EPS 601).  
 
 
2.2.4.4 Blue Native Polyacrylamid Gel Electrophoresis (BN-PAGE) 
 
Native protein complex separation was performed by Blue Native Polyacrylamide Gel 
Electrophoresis (BN-PAGE) (Schägger & Jagow, 1991; Dekker et al., 1996) in a 
gradient gel system (4-13%). Resolving gradient gel solution (13%) was composed of 
acrylamide/bis-acrylamide (49.5%/3%), 66.67mM 6-aminocaproic acid, 50mM Bis-
Tris/HCl pH 7.0 and 20% glycerol. Stacking gel solution contained 4% 
acrylamide/bis-acrylamide (49.5%/3%), 66.67mM 6 -aminocaproic acid and 50mM 
Bis-Tris/HCl pH 7.0. BN resolving gels were casted in a homemade gradient-mixer 
and polymerized with TEMED and APS. 
Isolated mitochondrial fractions and cell lysates were spun down (10,000 x g, 5 min., 
4 °C) and the pellet was resuspended in 1%-digitonin-containing solubilization buffer 
(Table 2.2) by pipeting 20 times, vigorously. The end concentration was 1-2 µg 
protein/µL solubilization buffer depending on how much amout of protein was 
required to detect certain proteins by western blotting. Mitochondrial/cellular 
fractions were incubated on ice for 20 min. and mixed slightly every 5 min. The 
following centrifugation step (20,000 x g, 10 min, 4°C) cleared the solubilized 
mitochondrial/cellular micelles from insoluble material. 10x Blue-Native Loading dye 
(Table 2.2) was added to the supernatant, which were centrifuged for a last clearing 
step (20,000 x g, 3 min, 4°C). Depending on the proteins of interest, which were 
supposed to be detected by western blotting, from 25 µg (respiratory chain 
complexes) up to 200 µg (MCU-containing complexes) were loaded to each BN-
PAGE slot.  
Protein complex separation via BN-PAGE was performed in a cooled tank (SE600 
Ruby, Hoefer, Amersham Biosciences). BN-PAGE gels were run at 4 °C first at 400V 
and 15 mA/gel for 1,5 hours and Coomassie Brilliant Blue G-250-containing cathode 
buffer was exchanged with cathode buffer without Coomassie Brilliant Blue G-250. 
Following this, BN-PAGE gel was running at 100V and 15 mA/gel overnight.  
 
2.2.4.5 2D-BN-SDS-PAGE analysis 
 
After native protein complex separation in BN-PAGE (2.2.4.4) single BN stripes were 
cut out and assembled into a denaturating SDS-PAGE apparatus to separate and 
detect proteins of interest, which were not detectable in first BN dimension via 
Western Blot analysis. As described in 2.2.4.4 mitochondrial or cellular fractions 
were solubilized and separated on BN-PAGE. Completely cutted single BN lanes 
were denatured in 1% DTT-containing 1x SDS running buffer for 30 min. at RT. The 
BN lane was assembled into glass plates for a regular-sized SDS-PAGE gels (2.2.4.2). 
Base gel and afterwards the SDS resolving gel solution (16,5%) were casting as 
described above (2.2.4.2). After running gel polymerization the BN stripe was 
implemented into the SDS stacking gel (4%). A two-well comb was added to stacking 
gel to gain two lanes for the molecular weight marker and the input control. Run 
16,5%-SDS-PAGE at 80 V, 25 mA/gel, 12 hours. 
 
2.2.4.6 Western Blotting and Immunodetection 
 
Semi-dry blotting chambers by PEQLAB (Biotechnologie GmbH) were used to 
transfer proteins and protein complexes after electrophoretic separation in 
polyacrylamide gels to Polyvinylidene fluoride (PVDF) membranes (Merck). Those 
were activated by methanol and washed with 1x blotting buffer (Table 2.2). Both, the 
polyacrylamide gel and the PVDF membrane were assembled with filter papers 
(Heinemann Labortechnik) soaked in 1x blotting buffer and incorporated into blotting 
chamber. SDS-PAGE gels were transfered at 25V, 250 mA, 2.5 hours and BN-PAGE 
gels at 25V, 400 mA, 3 hours.  
Afterwards, the PVDF membrane was stained with Coomassie Brilliant Blue solution 
(Table 2.2) for 3 min. and destained for 5 min. to visualize Coomassie-bound protein 
bands. The membrane was cut according to the molecular size of the proteins to be 
analysed for immunodetection. Methanol was utilized to destain and reactivate the 
membrane to prevent interference with immunodetection. The membrane was blocked 
for at least 2 hours at RT in skimmed milk (10% milk powder in 1x TBS-T (Table 
2.2)). After blocking, membrane stripes underwent primary antibody decoration 
overnight at 4°C. Homemade antibodies were diluted in 5% skimmed milk and 
commercial antibodies were hosted by 1x TBS-T (Table 2.6). Membranes were 
mildly washed in 1x TBS-T three times at RT for 10 min. Horseradish peroxidase-
conjugated seecondary antibody (Table 2.7, 1/5000 or 1/10000 in 5% skimmed milk) 
was added to the membrane for 1 hour at RT. The membrane was washed three times 
in TBS-T at RT. For immunodetection membranes were incubated with Pierce® ECL 
Western Blotting Detection Reagent (Thermo Scientific) and exposed to X-ray films. 




Digital autoradiography was used to visualize and to assess radioactivly labeled 
proteins. Radioactive samples were separated via electrophoresis and blotted to PVDF 
membranes as described above (2.2.4.6). The membrane was stained and destained 
with Coomassie and destainer solution (Table 2.2) for several minutes and dried by a 
hairdryer. The molecular weight marker was marked with radioactive ink and was 
sellotaped twice. Radioactive signals were exposed for at least one day to storage 
phosphor screens (GE Healthcare). A Storm820 scanner scanned and digitalized the 




2.2.5.1 Crude isolation of mitochondrial fractions from mammalian cells via 
differential centrifugation 
 
MEF cells were seeded and harvested at a confluency of 80-100 % 1-3 days later. In 
advance, 50 ml falcon tubes (Sarstedt) were weighed to determine the cell pellet 
weight later. Medium in 20 cm plates were discarded and washed with PBS once. 5 
ml PBS per plate was added and cells were scraped with rubber policeman and 
transferred to 50 ml falcon tubes to be centrifuged at 400g, 5 min., 4 °C. Cell pellets 
were resuspendend in cold Isotonic buffer (Table 2.2) and centrifuged at 1000g, 5 
min, 4 °C. Supernatants were carefully pipetted off and cell pellets were weighed.  
Cells were resuspended in Hypotonic buffer (Table 2.2) with plastic Pasteur pipettes 
(5 ml/g cells).  
Cells were homogenized gently with 10 handstrokes by glass-glass Dounce 
homogenizer (Sartorius). Cells were allowed to swell for 5-7 minutes to release 
mitochondria upon hypotonic conditions. Hypertonic buffer (Table 2.2) was added 
(1,1 ml/g cells) to obtain isotonic conditions and one volume of BSA-containing 
Isotonic buffer was added. Cell suspension was centrifuged at 1000g, 10 min,., 4 °C 
and mitochondria-enriched supernatant was centrifuged again to discard residual 
unsolved material. Mitochondrial fractions were gained by a 10.000g step. 
Supernatant was discarded and mitochondrial pellet was resuspended with 50-200 µl 
Isotonic buffer receiving an end concentration of around 10 µg/µl.  
 
2.2.5.2 Carbonate extraction 
 
Carbonate extraction was used to determine the topology of mitochondrial membrane 
proteins. Carbonate solutions (pH 10,8 and pH 11,5) were made freshly. Three times 
60 µg mitochondria were pelleted at 10000g, 5 min., 4 °C and resuspended in three 
different solutions, respectively. First 60 µg of mitochondria were resuspended in 100 
µl pH 10,8 carbonate solution and second 60 µg in 100 µl pH 11,5 carbonate solution. 
Third 60 µg mitochondria were resuspended in 100 µl 0,1% Triton X-100 solution. 
All incubations were on ice for 20 min. All suspensions were centrifuged at 100.000g, 
45 min., 4 °C. Supernatants were divided from pellets and pellets were resuspenden in 
100 µl SEM buffer. Proteins from all solutions were precipitated by TCA 
precipitation (trichloroacetic acid) for 30 min. on ice. Therefore 21 µL 72% TCA 
were added at RT to gain 17% TCA solution, samples were vortexed and incubated 
for 30 min.. Precipitates were centrifuged at 20000g for 30 min. at 4 °C and pellets 
were resuspended with 2x Laemmli buffer and resolved via SDS-PAGE analysis 
(2.2.4.2). 
 
2.2.5.3 Submitochondrial localization studies by swelling of mitochondria 
 
100 µg of pelleted mitochondria were resuspended in 100 µl of isotonic SEM buffer 
to maintain mitochondrial membranes. This was was aliquoted to 3x 30 µl. In parallel, 
100 µg of pelleted mitochondria were gently resuspended in hypotonic EM buffer to 
swell mitochondria, disrupt the outer membrane and gain mitoplasts. Mitochondrial 
solutions in isotonic as well as in hypotonic buffer were incubated on ice for 25 min.. 
Afterwards, proteinase K (PK) was added to the three aliquots per treatment in 
different amounts (0, 5 and 10 µl). PK had access to inner mitochondrial membrane 
localized proteins, whereas PK could only degrade outer mitochondrial proteins in 
SEM resuspended intact mitochondria. Meanwhile, additional 60 µg mitochondria 
were resuspended in 60 µl EM buffer. 10 µl PK was added to one of those samples 
and both samples were sonicated for 20 seconds each. Sonication generated micelles 
from mitochondria causing complete access of PK to mitochondrial proteins of all 
compartments. All samples were PK-treated for 10 min. on ice and samples were 
centrifuged at 13000 g at 4 °C. Mitochondrial pellets were resuspended in 1x 
Laemmli buffer. Samples were boiled at 95 °C for 10 min. to inactivate PK activity. 
Denatured samples should be loaded and resolved on SDS-PAGE immediately 
(2.2.4.2).  
 
2.2.5.4 FLAG immunoprecipitation  
 
FLAG immunoprecipitation (FLAG-IP) was performed from whole cells or from 
isolated mitochondria. FLAG-tagged proteins were transiently transfected to MEF 
cells via electroporation (2.2.1.3) and FLAG-IP was performed 3 days later. A 
untransfected WT control was seeded in parallel as a negative control of the FLAG-
IP. Purified mitochondria or cell suspensions were centrifuged at 10 000 g for 5 min. 
The amount of mitochondria was dependeing on the purpose of the IP and could 
range between 0,5 mg and 5 mg of mitochondria or cell lysates. The supernatant was 
removed and the pellet was resuspended in 200 µl solubilization buffer (final: 50 mM 
Tris/HCl, 50 mM NaCl, 10 % Glycerol, 5 mM EGTA, 1 % Digitonin, 200 µM PMSF) 
by pipetting 20 times up and down. 600 µL of solubilization buffer was added and 
again mixed by pipetting for 10 times. Lysates were incubated on ice for 30 min. and 
centrifuged at 20 000 g for 10 min at 4°C. Unsolubilized debris was removed. 
Supernatant was taken and added to a prepared mobicol column (M2 Affinity Matrix 
(Sigma), 4G). To equilibrate the column, 40 µl FLAG beads slurry were added to the 
mobicol column and washed 3 times by adding washing buffer (final: 50 mM 
Tris/HCl, 50 mM NaCl, 10 % Glycerol, 5 mM EGTA, 0,3 % Digitonin, 200 µM 
PMSF) and centrifugation at 100 g, 30 sec.. The lysate was incubated with the FLAG 
beads for 1 hour at 4 °C on a rotating wheel. Afterwards, unbound material was 
centrifuged at 200g, 1 min.. FLAG beads were washed 5 times with 500 µl washing 
buffer (centrifugation steps 100 g, 30 sec, 4 °C). To elute proteins interacting with 
FLAG beads, 40 µg FLAG peptides (180 µl washing buffer and 20 µl FLAG 
peptides) were added to the column and incubated for 30 min. at 4 °C. Lysate were 
centrifuged for 1 min. at 200 g. Elution was mixed with SDS- or BN-PAGE loading 
dye (Table 2.2), depending on the aim of the experiment and loaded on SDS- (2.2.4.2) 
or BN-PAGE (2.2.4.4) for further separation.  
 
2.2.5.5 Antibody coating to Protein-A-Sepharose (PAS)  
 
To address endogenous protein-protein interactions, co-immunoprecipitations (Co-IP) 
were performed with antibodies (raised in rabbit) coated to Protein-A-Sepahrose 
(PAS). Therefore, 75 µl 50% PAS were added to mobicol column (M2 Affinity 
Matrix (Sigma), 4G) and washed twice with 500 µl 0.1 M KPi pH 7,4 by centrifuging 
at 100 g for 30 sec. In parallel, 150 µl antibody serum were diluted in 150 µl KPi 
solution. PAS beads and antibodies were incubated for 1 hour at RT while mixing on 
a rotating wheel. The crosslinker dimethyl pimelimidate (DMP) was thawed and a 5 
mg/ml solution in 0,1 M sodium borate pH 9,0 was prepared. The column was washed 
twice with 0.1 M sodium borate and 350 µl of the DMP solution was added. Beads 
and DMP were incubated for 30 min at RT while mixing. DMP was removed by 
cnetrifugation (200g, 1 min, 4 °C). Column was washed twice with 500 µl 1 M Tris 
pH 7,4. Beads were incubated with Tris for additional 2 hours at RT and stored at 4 
°C. 
 
2.2.5.6 Co-immunoprecipitation (Co-IP) with antibodies coated to PAS 
 
Purified mitochondria or cell suspensions were centrifuged at 10 000 g for 5 min. The 
amount of mitochondria was dependeing on the purpose of the IP and could range 
between 0,5 mg and 5 mg of mitochondria or cell lysates. The supernatant was 
removed and the pellet was resuspended in 200 µl solubilization buffer (final: 50 mM 
Tris/HCl, 50 mM NaCl, 10 % Glycerol, 5 mM EGTA, 1 % Digitonin, 200 µM PMSF) 
by pipetting 20 times up and down. 600 µL of solubilization buffer was added and 
again mixed by pipetting for 10 times. Lysates were incubated on ice for 30 min. and 
centrifuged at 20 000 g for 10 min at 4°C. Unsolubilized debris was removed. 
Supernatant was taken and added to a prepared mobicol column (M2 Affinity Matrix 
(Sigma), 4G). To equilibrate the column, it was washed 3 times by adding washing 
buffer (final: 50 mM Tris/HCl, 50 mM NaCl, 10 % Glycerol, 5 mM EGTA, 0,3 % 
Digitonin, 200 µM PMSF) and centrifugation at 100 g, 30 sec. The lysate was 
incubated with the beads for 1 hour at 4 °C on a rotating wheel. Afterwards, unbound 
material was centrifuged at 200g, 1 min. Beads were washed 5 times with 500 µl 
washing buffer (centrifugation steps 100 g, 30 sec, 4 °C). To elute proteins interacting 
with the coated antibody, glycin (0,1 M, pH 2,8) was added to the column and 
incubated for 7 min. at RT. Lysate was centrifuged for 1 min. at 200 g. Elution was 
mixed with 2x SDS loading dye (2.2.4.2), and subjected to further SDS-PAGE 
analysis. The unbound fraction of the Co-IP was subjected to 2D-BN-SDS-PAGE 
analysis (2.2.4.5) to study compositions of protein complexes.  
	 	 	 	 	  
2.2.6 Specialized techniques 
 
2.2.6.1 Radiolabeled in-vitro preprotein import into mitochondria 
 
Mitochondria from MEF cells were isolated via differential centrifugation. After the 
finalizing centrifugation step (10.000g), mitochondria were resuspendend in Isolation 
buffer (Table 2.2) and adjusted to a relatively high-end concentration of around 20 
µg/µl. Further pelleting and an additional resuspension step should have been 
prevented to avoid mechanical stress. Concentrated mitochondrial suspensions were 
aliquoted to single import time points. Simutaneously, preprotein lysate was prepared 
by in-vitro translation (2.2.3.8). One import reaction contained 30 µg in 30 µl 
mammalian Import reaction buffer (Table 2.2) and 1,5-3 µl preprotein lysate (2-10 %) 
were added for depicted time points at 30 °C and gentle shaking. 1 µl AVO mix 
(final: 8µM antimycin, 1µM valinomycin, 20µM oligomycin) was given to the 
negative control sample for 3 min. to dissipate the membrane potential and to inhibit 
preprotein import. The same volume of Ethanol was added to the other samples. After 
3, 7 and 15 min. respectively, mitochondrial import reactions were stopped by adding 
1 µl AVO mix and putting the samples back on ice. Samples were treated with 
Proteinase K (1 mg/ml) for 10 min. on ice and this digestion of non-imported 
precursors was inactivated with PMSF (200 mM in Ethanol) for 10 min. on ice. 
Mitochondria were centrifuged at 18.000g, 10 min., 4 °C. Supernatant was discarded, 
150 µl SEM buffer (Table 2.2) was added to wash out residual radioactivity and 
samples were pelleted again. Samples were further analysed by separation on SDS-
PAGE (2.2.4.2) to separate the imported mature form and non-imported preprotein 
under various time points to visualize the kinetics of in-vitro import reaction. As a 
second opportunity, mitochondria were solubilized by Blue-native solubilization 
buffer (Table 2.2) and applied to protein complex separation on BN-PAGE (2.2.4.4). 
Gels were proceeded for western blotting and analysis via digital autoradiography 
(2.2.4.7).  
 
2.2.6.2 Lipid extraction and Thin Layer Chromatography (TLC) 
 
Thin layer chromatography (TLC) is a chromatographic method, which was used to 
separate phospholipids. In the first place, lipids from purified mitochodnria were 
extracted. 1 mg of purified mitochondria were resuspended with 1,5 ml Chloroform-
methanol (2:1, v/v) in a small glass test tube and shaken for 1 hour vigorously. While 
shaking the glass tubes resealed with parafilm at 4 °C. Water (300 µl) was added to 
the samples and vortexed for 1 min. The samples were centrifuged at 1000 rpm for 5 
min. The glass tubes were fixed with a strip of filter paper in a 15 ml falcon, so that 
they can be put into the centrifuge. The upper phase was the aqueous phase and was 
discarded after a centrifugation step. The lower phase was the solvent phase and was 
washed with a methanol/water mix (1:1, v/v). The mix was vortexed and centrifuged 
as before. The solvent phase was transferred to a new glass tube. The samples were 
kept under a fume hood over night to dry the samples. The lipids were dissolved in 
100 µl of chloroform and subjected to further TLC analysis. The TLC glass plate was 
marked with pencil. From the bottom 2 cm space was left. Samples were applied to 
the TLC plate using glass capillaries and were spot several times on top of eachother. 
The TLC tank was filled with 100 ml of Chloroform/Triethylamine/Ethanol/Water 
(30:35:35:7). 30 min prior to the run. The plate was put inside the TLC tank, which 
was filled with mobile phase solvent and the lid was closed. The run took about 3-4 
hours to complete. In addtion to the samples some lipid standards were spotted beside. 
Only one drop was sufficient. Common standards were cardiolipin, 
phosphatidylcholin and phosphatidylglycerol. After the TLC run the glass plate i 
staken from the chamber and dried under a fume hood for several min. An oven was 
preheated at 180 °C. The plate was submerged in the staining solution (10 % CuSO4 
in 10 % o-Phosphoric acid) and kept for 3-5 seconds. The plate was immediately 
incubated at 180 °C for 10 min until the spots on the plates appeared stong enough. 
 
2.2.6.3 ROS measurement by H2DCFDA 
 
Reactive oxygen species (ROS) was detected by CM-H2DCFDA (5-(and-6)-
chloromethyl-2′,7’-dichlorodihydro fluorescein diacetate, acetyl ester). Isolated 
mitochondria from MEF cells were resuspended in assay buffer (Table 2.2). 100 µg 
mitochondria were added to 0,3 ml assay buffer containing 2 µl 100 mM CM-
H2DCFDA dye. Using a fluorescence spectrophotometer (Hitachi F-7000) changes in 
fluorescence was determined for 700 seconds (Excitation 498 nm/ emission 525 nm). 
ROS measurements were performed in triplicates.  
 
2.2.6.4 Measurements of mitochondrial calcium uptake 
 
Mitochondrial calcium uptake in MEF cells was measured in 1 mM calcium (Krebs-
Ringer) solution under the Cell Observer High Speed microscope fluorescence 
microscope (Zeiss). Mitochondrial calcium could interact with a calcium-binding site 
of the ratiometric sensor D3circular permuted Venus (D3cpv) causing that the donor 
fluorophor CFP come into Foerster radius with the acceptor YFP. D3cpv was a 
genetically encoded, mitochondrial matrix-targeted calcium sensor, which was 
transfected to MEF cells via electroporation (2.2.1.3). Only MEF cells with 
mitochondrial imported calcium sensor were measured. The signal of the donor 
fluorophor was substracted from the resulting FRET signal. The ratio of the FRET to 
donor (CFP) signal was calculated by the AxioVision software (Zeiss). Technically, 
transfected cells were seeded on coverslips and grown for 24 hours. Afterwards, the 
cover slip, which contained the adherent cells was put into a reservoir, where 1 ml of 
Krebs Ringer solution was added. Then, basal mitochondrial calcium levels were 
monitored via the FRET/donor ratio under the microscope for 2 min. 100 µM ATP 
were added to stimulate calcium uptake into the cell and the development of 
stimulated mitochondrial calcium uptake was monitored for 5 min. Measurements 




3.1 Characterisation of MCU constituents in WT and TAZ KO MEF cells 
 
3.1.1 Steady state levels of mitochondrial proteins 
 
Steady state levels of mitochondrial proteins were studied to obtain putative 
alterations in protein biosynthesis and turnover, mitochondrial protein import or 
posttranslational modifications. Alterations of protein steady state levels in BTHS 
models were already observed. Complex II levels are reduced in BTHS mouse hearts, 
whereas respiratory chain protein levels of complex I, III and IV are unaffected 
(Dudek et al., 2016). MEF cells were the main model system of this study and steady 
state levels of mitochondrial proteins in WT and TAZ KO MEF cells were addressed. 
Mitochondrial proteins of the respiratory chain complexes were detected after 
separation on SDS-PAGE and immunoblotting. Constituents of complex I 
(NDUFB8), complex II (SDHA, SDHB), complex III (RIESKE and complex V 
(ATP5B) did not show any altered protein levels in TAZ KO MEF mitochondria. 
However, the CIV components COX1, COX2 and COX4I-1 displayed reduced 
protein steady state levels in TAZ KO MEF mitochondria (Figure 3.1B). The protein 
levels of Mitochondrial Calcium Uniporter (MCU) constituents MCU, EMRE, 
MICU1, and MCUR1 were not affected in TAZ KO (Figure 3.1A). MCUb levels 
showed a slight reduction.  
Concluding, protein steady state levels of MCU were not altered in TAZ KO MEF 
mitochondria. 
 
Figure 3.1: Steady state levels of MCU components are not affected in TAZ KO MEF cells 
(A) Purified mitochondria from WT and TAZ KO MEF cells were isolated by differential 
centrifugation and separated on a 10-18% gradient SDS-PAGE. Indicated proteins were detected by 
immunoblotting.  
(B) Mitochondria  WT and TAZ KO MEF cells were isolated by differential centrifugation and from
separated on a 12,5% SDS-PAGE. Indicated proteins were detected by immunoblotting.  
 
3.1.2 Mitochondrial localization of core constituents of MCU 
 
It is under debate, if the MICU gatekeepers reside in the intermembrane space (IMS) 
(Tsai et al., 2017). To address the localization and topology of MICU, a protease 
protection assay was carried out. In intact mitochondria, mitochondrial proteins of the 
inner mitochondrial membrane (IMM) or matrix were protected against proteinase K 
(PK) treatment (Figure 3.2A). Proteins of the outer mitochondrial membrane (OMM), 
such as TOM20, were cleaved upon PK treatment. Mitoplasts were generated by 
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accessed and cleaved proteins exposed to the IMS, such as TIM23. MICU1 and 
MICU2 were degraded by PK in mitoplasts, but not in mitochondria, indicating that 
the MICU gatekeepers were localized at the IMS side of the IMM. Instead, TIM44 is 
localized to the mitochondrial matrix and protected against PK treatment. Sonication 
and PK treatment of mitoplasts degraded mitochondrial proteins of all compartments.  
Furthermore, the topology and the membrane-association of MICU gatekeepers was 
defined in WT and TAZ KO MEF mitochondria. MICU1 and MICU2 contain a N-
terminal MTS, which is cleaved after protein import (Petrungaro et al., 2015), but it 
was still unclear, whether MICU1 and MICU2 are integral membrane proteins or just 
inner membrane-associated in the IMS. Carbonate and Triton X-100 extractions of 
membrane-bound mitochondrial proteins provide information, if a mitochondrial 
protein contains a transmembrane span (Figure 3.2B). Carbonate solution of pH 10,8 
extracted the membrane-associated protein TACO1 from the pellet fraction partly and 
could extract TACO1 completely into the soluble fractions upon pH 11,5. The 
integral membrane protein TOM20 was extracted from membranes only by Triton X-
100. The majority of MICU2 was extracted into the soluble fraction by carbonate 
treatment in both carbonate conditions, indicating that MICU2 is not an integral 
protein, but membrane-associated. MICU1 and MICU2 contain cardiolipin-binding 
domains (Kamer et al., 2017) and cardiolipin remodeling might be essential for 
membrane association. Thus, the carbonate extraction pattern of MICU2 in WT 
mitochondria was compared with its pattern in TAZ KO. The hypothesis was, that 
less membrane association could be displayed by a higher share of soluble MICU2, 
but MICU2 extraction pattern did not show differences. MICU2 association to the 
inner membrane was not taffazin-dependent. In fact, TACO1 was more extracted 
from membranes in TAZ KO.  
Concluding, the MCU gatekeepers MICU1 and MICU2 are associated to the inner 
mitochondrial membrane and exposed to the innermembrane space. MICU2 is not a 
transmembrane span-containing mitochondrial protein and MICU2 association to the 





Figure 3.2: Micu1 and Micu2 are associated to the inner mitochondrial membrane and exposed 
to the innermembrane space  
(A) Mitochondria from WT MEF cells were resuspended in isotonic buffer to maintain mitochondrial 
outer membrane. Mitochondria were swelled in hypotonic buffer for 15 minutes to gain mitoplasts. 
Samples were separated on a SDS-PAGE resolving gel (12,5%). Indicated proteins were detected by 
immunoblotting. (IMM, Inner mitochondrial membrane; OMM, Outer mitochondrial membrane, PK, 
Proteinase K, * unspecific band 
(B) Mitochondria from WT and TAZ KO MEF cells were resuspended in freshly prepared carbonate 
(pH 10,8 and pH 11,5, respectively) and Triton X-100 solutions. Samples were pelleted at 100.000g for 
45 minutes. Pellets and supernatants were divided and separated on a SDS-PAGE resolving gel 
(12,5%). Indicated proteins were detected by immunoblotting. T, Total, P, Pellet, S, Soluble fraction,  
* unspecific band 
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3.2.1 2D-BN-SDS-PAGE analysis of MCU/EMRE-containing complexes in MEF 
cells 
 
MCU complexes in the MegaDalton (MDa) range of mouse brains and HEK cells 
undergo reorganization processes depending on the turnover and expression of EMRE 
(König et al., 2016). To address, if MCU complexes display altered organization or 
composition in a different lipid environment, mitochondria were purified, solubilized 
in digitonin, and protein complexes separated by BN-PAGE analysis. MCU 
complexes were detected by immunoblotting, and two separate MCU complexes with 
different molecular weights were detected (Figure 3.3A). WT mitochondria contained 
a 1000 kDa (named MCU-2) and a 500 kDa MCU complex (named MCU-3), where 
MCU was more abundant in the higher molecular weight form. MCU complexes in 
TAZ KO mitochondria showed a ratio shift. MCU was more distributed to the lower 
complex in TAZ KO. Both MCU complexes in TAZ KO were slightly shifted 
potentially caused by the different lipid composition of the micelles in BN-PAGE 
analyses. The interaction partner EMRE could not be detected in the first BN-PAGE 
dimension. The separated mitochondrial fractions were again separated on a SDS-
PAGE in the second dimension (Figure 3.3B). A third MCU complex in the higher 
MDa range was apparent (named MCU-1 complex), which was not present in TAZ 
KO mitochondria. These analyses showed the MCU complex ratio shift between both 
phenotypes. EMRE signals comigrated with MCU signals. The MCU antibody 
detected an additional signal in the MDa range, which was not comigrating with 
EMRE signals.  
Concluding, EMRE-containing MCU complexes display altered complex 
organization in TAZ KO MEF mitochondria. MCU protein is shifted to lower 
molecular weight forms of MCU in TAZ KO MEF cells. 
 
 
Figure 3.3: EMRE-containing MCU complexes undergo a ratio shift in TAZ KO MEF 
mitochondria 
(A) Mitochondria from WT and TAZ KO MEF cells were solubilized by 1% digitonin and separated 
by a gradient BN-PAGE resolving gel (4-13%). Indicated proteins were detected by immunoblotting.  
(B) Mitochondria from WT and TAZ KO MEF cells were solubilized and separated as described in 
(A). Single BN-PAGE lanes were cutted out and separated on SDS-PAGE in the second dimension 
(2D-BN-SDS-PAGE analysis). Protein complexes were detected by western blotting against MCU, 
EMRE and ATP5B 
 
 
3.2.2 EMRE-containing complexes interact with MCU oligomers 
 
To get more information about the composition of MCU complexes in the MDa 
range, an EMRE depletion coimmunprecipitation (Co-IP) analysis was performed. 
EMRE and its interaction partner MCU were pulled down by an EMRE antibody 
(Figure 3.4A). The two protein bands detected by the MCU antibody displayed 
different interaction pattern with EMRE. The upper band was pulled down by the 
EMRE antibody and the lower band was unaffected. The unbound fractions of the Co-
IP were analysed by 2D-BN-SDS-PAGE analyses (Figure 3.4B). The two MDa MCU 
complexes (named MCU-1 and MCU-2, Figure 3.4B lane 1) were exposed in the 













     ATP5B
EMRE
 WT  TAZ KO

















pulldown of EMRE. Thus, EMRE-containing complexes were not just comigrating 
with MCU complexes, those complexes were EMRE-containing MCU complexes. 
However, the unknown signal in the MDa range remained stable (Figure 3.4B, lane 1 
and 4) and it was not coimmunoprecipitated with EMRE and MCU. Therefore, the 
unknown signal in the MDa range was not an EMRE-containing protein complex.  
 
 
Figure 3.4: EMRE-containing complexes interact with MCU oligomers  
(A) Mitochondria from WT MEF cells were coimmunprecipitated by EMRE and Tafazzin antibody in 
1% digitonin and EGTA-containing solubilization buffer. Samples were separated on 10-18 % gradient 
SDS-PAGE and immunoblotted against EMRE and MCU  
(B) Native unbound fractions from (A) were separated by 2D-SDS-BN-PAGE analysis and 
immunoblotted against EMRE, MCU and ATP5B. 
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The second approach to charaterize the double band detected by the MCU antibody 
after immunoblotting was a knockdown of MCU mRNA and protein levels. MCU 
RNA silencing by siRNA could address the specificity of the MCU antibody. After 3 
days of MCU RNA knockdown MEF cell lysates (Figure 3.5A) and mitochondria 
(Figure 3.5B) were harvested. The comparison of MCU from WT and non-target 
siRNA (NT) transfection showed that the treatment itself did not affect MCU levels 
(Figure 3.5A). Two siRNAs against MCU mRNA were tested and it was proceeded 
with siRNA number 2. The knockdown of MCU after mitochondria isolation revealed 
that EMRE and Micu1 levels were reduced as well (Figure 3.5B). The upper band of 
the MCU antibody double band was strongly reduced and the lower band remained 
unaffected (Figure 3.5A+B). These findings clarified that the lower band was not 
MCU.  
 
Figure 3.5: MCU antibody (sigma) reveals a double band and the upper one is specific 
(A) Non-target control siRNA (NT con.) and siRNA against MCU mRNA were transfected to WT 
MEF cells (50 ng/µL). After 3 days cells were harvested and lysed by a denaturing buffer. Samples 
were separated on SDS-PAGE (12,5%) and immunoblotted against MCU and ATP5B 
(B) After MCU mRNA silencing as described in (A), mitochondria was isolated by differential 
centrifugation. Samples were separated on a 10-18% gradient SDS-PAGE and immunoblotted against 
EMRE, MCU, Micu1 and ATP5B 
 
3.2.4 The interaction of MCU and EMRE is not affected in TAZ KO MEF 
mitochondria 
 
The MCU complexes shifted between higher and lower molecular weight forms 
depending on tafazzin activity as shown before (Figure 3.3). The MCU complexes 
have always been interacting with EMRE. The interaction of MCU and EMRE was 
addressed. Therefore, FLAG-tagged human MCU was overexpressed in WT MEF 
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3.6A). The degree of EMRE and MCU-FLAG interaction was unaffected in TAZ KO 
MEF cells. The sequence homology of murin and human mature MCU is 100%, so 
that the different origins of MCU-FLAG (human) and EMRE (mouse) did not affect 
the interaction. This was confirmed by coimmunprecipitation of MCU-FLAG and 
EMRE and visualization of EMRE-containing MCU complexes after 2D-BN-SDS-
PAGE analysis (Figure 3.6B). The native eluate of the MCU-FLAG-IP from WT cells 
was loaded and separated on BN-PAGE. MCU-FLAG was organized in the two MDa 
MCU complexes (complexes MCU-1 and MCU-2) recapitulating earlier experiments 
(Figures 3.3 and 3.4). Immunoblotting against endogenous MCU complexes showed 
that MCU-FLAG contained endogenous MCU as well. Indicating, that MCU-FLAG 
and endogenous MCU formed heterogenous MCU pores which were interacting with 
EMRE. The finding of unaltered MCU-EMRE interaction in TAZ KO MEF cells was 
further confirmed by coimmunprecipitation of EMRE as a different bait (Figure 
3.6C). Other MCU interaction partners known from the literature, such as MCUb, 
MCUR1 and the gatekeepers MICU1 and MICU2 could not be detected by diverse 
approaches (specific depletion IPs, RNAi, antibody shift assays or variation of 
antibodies for IP or immunoblotting).  
The Co-IP studies of MCU and EMRE displayed, that the interaction of MCU and 




Figure 3.6: Interaction of MCU and EMRE is unaffected in TAZ KO MEF cells 
(A) WT and TAZ KO MEF cells were transiently transfected with human MCU-FLAG construct. After 
3 days, FLAG-immunoprecipitation was performed and samples separated on 12,5% SDS-PAGE 
(B) MCU-FLAG was overexpressed in WT MEF cells. Native eluate fractions from FLAG-
immunoprecipitation (A) were separated on BN-PAGE (4-13% resolving gel). Single BN gel stripes 
were further separated on SDS-PAGE (16,5% resolving gel) and immunoblotted against FLAG, EMRE 
and MCU.  
(C) Mitochondria from WT and TAZ KO cells were coimmunprecipitated by EMRE and tafazzin 
antibodies conjugated to protein A sepharose. Samples probed on SDS-PAGE were immunoblotted 
against EMRE, MCU and ATP5B 
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The EMRE depletion Co-IP in section 3.2.2 illustrated that MEF MCU complexes 
contained EMRE. To address the further composition of MCU, two hypotheses were 
considered. First, MCU complexes in the MDa range (MCU-1, MCU-2) could 
dissociate in MEF TAZ KO mitochondria, causing the lack of subunits in MDa MCU 
complexes. The MICU gatekeepers were considered to interact with MCU 
tendentially in one of the MDa MCU complexes and not in the kDa MCU complexes. 
The other possibility was, that the 1000 kDa (MCU-2) and the 500 kDa MCU (MCU-
3) complexes are just oligomers. Size-wise it was indicative that both complexes are 
MCU monomers and dimers. To test which of the both hypothesis was true, a MICU1 
depletion Co-IP was performed. The unbound fractions were loaded and separated on 
2D-BN-SDS-PAGE (Figure 3.7). The MICU1 antibody pulled down the higher MDa 
MCU complex (MCU-1) and the 1000 kDa complex (MCU-2) remained unaffected. 
This was an indication, that the MICU gatekeepers reside in the higher MDa form 
(MCU-1) and not in the kDa complexes (MCU-2 and MCU-3). The higher MDa 
complex (MCU-1) was not detectable in TAZ KO (Figure 3.3) indicating that MCU 
complexes in TAZ KO cells did not interact with MICU1.  
 
 
Figure 3.7: The MDa MCU complex contains the gatekeeper MICU1  
WT MEF cell lysates (1 mg) were solubilized by a 0.5% digitonin- and an EGTA-containing buffer. 
Micu1 antibody (Cell signaling) and the control antibody (raised against tafazzin, homemade) were 
coated to protein A sepharose. Micu1 and putative interaction partners were coimmunprecipitated from 
WT cell lysates. Unbound fractions of the coimmunprecipitation were separated on a 4-13% BN-PAGE 
resolving gel. Single BN gel stripes were further separated on SDS-PAGE (16,5% resolving gel) and 





















3.2.6 Complementation of TAZ KO MEF cells by exogenous tafazzin expression:  
Isolation of Taz-FLAG Isoform 2 and functional analysis via TLC 
 
It was necessary to clarify, if the MCU complex reorganization in TAZ KO cells was 
caused by the lack of tafazzin activity or by other unspecific origins. Therefore, 2 
different mouse TAZ-FLAG isoforms were cloned by Arpita Chowdhury and 
transiently transfected to MEF cells via electroporation. Both TAZ-FLAG isoforms 
were weakly expressed in MEF cell lysates and were not detectable via western 
blotting (Figure 3.8A). Thus, the FLAG-tagged tafazzin isoforms were 
immunoprecipitated and expression was confirmed. Isoform 2 was sufficiently 
expressed and further experiments were performed with this isoform.  
The expression of exogenous TAZ-FLAG in TAZ KO MEF cells was characterized 
on the functional level. Thin-layer-chromatography (TLC) showed, if the genetic 
modification of TAZ KO cells affected the lipid composition (Figure 3.8B). The ratio 
of cardiolipin (CL) to its precursor monolysocardiolipin (MLCL) might be reduced 
TAZ KO MEF cells. We wanted to check whether genetic complementation of 
tafazzin in TAZ KO cells could shift the CL/MLCL ratio to the WT lipid composition 
or not. WT MEF cells revealed cardiolipin, but no monolysocardiolipin. The 
precursor MLCL appeared in TAZ KO MEF cells and disappeared in TAZ-FLAG 
expressing TAZ KO cells. Levels of other phospholipid, such as PG and PC were not 
affected in this approach.  
Transient transfection and expression of Tafazzin-FLAG in TAZ KO MEF cells were 
established and rescued the CL/MLCL ratio in TAZ KO MEF cells. 
 
 
Figure 3.8: Altered lipid composition of TAZ KO MEF cells can be rescued by complementation 
with tafazzin.  
(A) Mouse tafazzin isoforms were transfected to TAZ KO MEF cells by electroporation. Native 
immunoprecipitation of FLAG-tagged taffazin was performed with 1 mg of total cell lysates. 
(B) Lipids were extracted from WT, TAZ KO and TAZ-FLAG containing TAZ KO MEF mitochondria 
by thin-layer chromatography (TLC). Lipid migration was controlled by parallel separation of standard 
lipid solutions (PC, phosphatidylcholine; CL, cardiolipin; MLCL, monolysocardiolipin; PG, 
phosphatidylglycerol) 
 
3.2.7 MCU complex dissociation and respiratory chain remodeling in TAZ KO 
MEF mitochondria are rescued by tafazzin complementation 
 
To address, if tafazzin complementation in TAZ KO MEF cells rescues the MCU 
complex organization, MCU complexes from TAZ-FLAG expressing TAZ KO MEF 
cells were separated on 2D-BN-SDS-PAGE. In fact, tafazzin complementation in 
TAZ KO MEF cells rescued the altered MCU organization in TAZ KO and returned it 
to the WT MCU complex distribution. This finding highlighted, that the 500 kDa 
MCU complex (MCU-3) did not require appropriate remodeling of cardiolipin for its 
structural integrity, whereas the stability of the 1000 kDa MCU complex was caused 
by appropriate tafazzin expression and function (Figure 3.9A).  
Respiratory chain complexes are remodeled in TAZ KO MEF cells and respirasomes 
were drastically reduced (Chowdhury et al., 2018). Expression of exogenous TAZ-
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FLAG in TAZ KO MEF cells could confirm the specific dependency of tafazzin on 
respiratory chain complex stability (Figure 3.9B). Respirasomes occured after tafazzin 
complementation in TAZ KO and the migration pattern of the single OXPHOS 
oligomers were comparable to WT. The different lipid/cardiolipin content in the 
micelles of solubilized mitochondria could alter the migration behavior on BN-PAGE.  
The data indicate, that MCU complex dissociation and respiratory chain remodeling 




Figure 3.9: MCU complex organization and respiratory chain remodeling is tafazzin-dependent. 
(A) Lysates from WT, TAZ KO, and tafazzin-complemented TAZ KO MEF cells were solubilized in 
1% digitonin and separated in a 4-13% BN-PAGE resolving gel. Single BN gel stripes were further 
separated on SDS-PAGE (16,5% resolving gel) and immunoblotted against MCU and ATP5B. 
(B) Lysates from WT, TAZ KO, and tafazzin-complemented TAZ KO MEF cells were solubilized in 
1% digitonin and separated on a 4-13% BN-PAGE resolving gel system. Respiratory chain complexes 
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3.2.8 MCU complex stability in MEF cells is dependent on appropriate 
cardiolipin biosynthesis, but not reactive oxygen species (ROS) 
 
The structural integrity of MCU depends on cardiolipin remodeling (3.2.7). We asked 
whether MCU complex organization is dependent on taffazin Furthermore, we 
monitored, if impaired cardiolipin biosynthesis affects MCU complex stability. 
Therefore, the cardiolipin synthase (CRLS1 gen) was silenced by an RNAi approach 
for 3 days (Figure 3.10A) and MCU complexes were separated from cell lysates. 
Non-targeted control MEF cells revealed a 500 kDa and a 1000 kDa MCU complex. 
SiCRLS1-treated MEF cells just contained the 500 kDa MCU complex (Figure 
3.10B). As a consequence, higher MCU oligomers, at least in the MDa range, require 
appropriate cardiolipin levels to maintain structural integrity.  
MCU activity and complex oligomerization were discussed to be regulated by the 
mitochondrial redox status via S-glutathionylation at the N-terminal domain (NTD) 
(Dong et al., 2017). In addition, MICU1 and MICU2 dimerization might be dependent 
on the redox status in the IMS (Petrungaro et al., 2015). To study the impact of 
reactive oxygen species (ROS) on protein complex organization mitochondrial ROS 
production was quenched by mitotempo for 24 hours and samples analyzed on 2D-
BN-SDS-PAGE (Figure 3.10C). The success of the treatment was confirmed by 
fluorescence-based ROS measurements via 2´, 7´-dichlorofluorescin (DCFDA).  ROS 
production in TAZ KO cells was significantly increased and were rescued by addition 
of mitotempo (Figure 3.10D).  The phenotype of increased ROS levels in TAZ KO 
MEF cells went along with Chowdhury et al., 2018. Hence, reduction of ROS does 
not alter MCU complex integrity in both, WT and TAZ KO MEF cells.  
 
Figure 3.10: MCU complex organization depends on cardiolipin biosynthesis 
(A) Cardiolipin synthase mRNA in MEF cells was silenced by siRNA for three days. After harvesting, 
cells were lysed and separated on 12,5% SDS-PAGE and immunoblotted against VDAC3 and 
cardiolipin synthase.  
(B) MEF cells from (A) were solubilized and resolved by 2D-BN-SDS-PAGE analysis. Protein 
complexes were detected by immunoblotting against MCU and ATP5B. 
(C). MEF cells were treated with the ROS scanvenger Mitotempo (50 µM final concentration) for 24 
hours. Cells were solubilized by digitonin and separated by 2D-BN-SDS-PAGE analysis. MCU 
complexes were detected by western blotting. 
(D) Function of ROS scavenger Mitotempo was examined with isolated mitochondria by fluorimetric 
ROS measurements via DCFDA (2´, 7´-dichlorofluorescin) (n = 3, mean ± SEM) 
 
 
3.2.9 Quantification of MCU complex ratio shift in WT and TAZ KO MEF cells 
 
The ratio shifts of MCU complexes in WT and TAZ KO MEF cells were quantified to 
address, if this phenotype is statistically relevant. The ratio shift of the 500 kDa and 
1000 kDa MCU complexes in WT and TAZ KO MEF cells were quantified by 
densiometric approach via ImageJ (Figure 3.11A). MCU complexes in WT showed a 
ratio shift from the higher to the lower molecular weight form of around 60-to-40 
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shift from the higher to the lower molecular weight form was approximately 10-to-90 
percent. This ratio shift appeared differently after MCU separation from cell lysate 
(Figure 3.11C) or isolated mitochondria (Figure 3.11B). The MCU complex ratio in 
both genotypes was more shifted to the lower molecular weight form after cell lysate 
separation in comparison to isolation from mitochondria and less in the higher 
oligomer in tendency. 
However, independently from the procedure of purifying mitochondria, the MCU 
complex ratio shifts in WT and TAZ KO MEF cells are statistically relevant. 
 
Figure 3.11: Higher-order MCU complexes shift to lower molecular weight forms in TAZ KO 
MEF cells 
(A, B, C) MCU complexes were quantified by densiometric analysis (ImageJ). The signal intensity of 
the 1000 kDa and the 500 kDa MCU complexes were set to 100% per genotype and the shares of both 
complexes per genotype were compared (n = 8, mean ± SEM). 
(A) Quantifications of MCU complex ratios in WT and TAZ KO MEF cells. Either whole cells were 
harvested and directly solubilized for 2D-BN-SDS-PAGE analysis or mitochondria from MEF cells 
were used (n = 8, mean ± SEM).  
(B) Quantifications of MCU complex ratios in WT and TAZ KO MEF mitochondria (n = 5, mean ± 
SEM).  
(C) Quantifications of MCU complex ratios in WT and TAZ KO MEF cell lysates (n = 3, mean ± 
SEM). 
 
3.3 Mitochondrial calcium uptake is affected in TAZ KO cells  
 
The reorganized MCU complexes in TAZ KO MEF cells could affect mitochondrial 
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transiently transfected with a mitochondrial matrix-targeted calcium sensor, called D3 
circularly permuted Venus (D3cpv) (Wallace et al., 2008). MEF cells were measured 
in 1 mM calcium (Krebs-Ringer) solution under a fluorescence microscope. 
Mitochondrial calcium could interact with a calcium-binding site of the sensor 
causing the donor fluorophor CFP come into Förster radius with the acceptor YFP. 
The signal of the donor fluorophor was substracted from the resulting FRET signal. 
Only MEF cells with mitochondrial imported calcium sensor were measured. This 
ratiometric calculation led to the finding, that the basal calcium uptake into TAZ KO 
MEF mitochondria was increased (Figure 3.12). This observation would fit to lack of 
MICU1 in MCU complexes in TAZ KO MEF mitochondria. MCU pores are 
constitutive active when gatekeepers are not interacting (Koenig et al., 2016; Tsai et 
al., 2017). The observation from figure 3.3 and 3.4 indicated, that MICU gatekeepers 
were reduced on the MCU pore in TAZ KO. However, the role of MCUR1 and 
MCUb and other unknown MCU interaction partners could not be determined in this 
study. The composition of the 1000 kDa and 500 kDa MCU complexes is still 
unsolved (beside MCU and EMRE) and a conclusive model of lacking gatekeepers, 
which indicate higher basal calcium uptake was too early at this stage of knowledge. 
The measurements of mitochondrial calcium uptake were performed by Zurine 
Bonilla del Rio in the lab of Ivan Bogeski.  




Figure 3.12 Basal mitochondrial calcium uptake is increased in TAZ KO MEF cells 
Mitochondrial calcium uptake of cultured WT and TAZ KO MEF cells was detected by the genetically 
encoded, mitochondrial matrix-targeted calcium sensor D3cpv. Cells were measured in 1 mM Krebs-
Ringer solution at Cell Observer High Speed microscope (Zeiss). The ratio of FRET to donor (CFP) 
signal was calculated by AxioVision software (Zeiss) (n = 3, mean ± SEM, ANOVA one-way). The 
measurements of mitochondrial calcium uptake were performed by Zurine Bonilla del Rio in the lab of 
Ivan Bogeski. 
 
3.4 Import and assembly of MCU and EMRE in WT/TAZ KO MEF 
mitochondria 
 
3.4.1 Tafazzin deficiency does not affect translocases in MEF cells 
 
The altered MCU complex organization in TAZ KO MEF cells gave rise to the 
question, if MCU complex assembly of newly synthetized and imported MCU 
components is affected in TAZ KO mitochondria. In the first place, the protein steady 
state levels of core constituents of mitochondrial translocases TIM23, TIM22 and 
TOM were examined (Figure 3.13A). The protein levels of TIM23 constituents 
TIM21, TIM23, TIM50 were not affected in TAZ KO cells. The core components of 
the TOM complex TOM40 and TOM70 were not altered as well. The TIM22 
complex constituent acylglycerol kinase (AGK) is involved in generation of 
phosphatidic acid (PA), a precursor of cardiolipin biosynthesis (Vukotic et al., 2017). 
AGK has a dual function as a TIM22 complex scaffold protein and it phosphorylates 
mono- and diacylglycerols in phospholipid biosynthesis. The protein steady state 
levels of AGK were examined, to address, if the lack of TAZ affected upstream 
cardiolipin biosynthesis pathway. However, TIM22 core components TIM22 and 
AGK levels were also not altered in TAZ KO (Figure 3.13A). The steady state levels 
of translocase complexes were examined by 2D-BN-SDS-PAGE analysis (Figure 
3.13C). This method gave indications if lacking tafazzin affected the structural 
integrity of translocases. The core complex of TIM23 (100 kDa) and the core 
complexes of TOM and TIM22 (400 kDa) were not affected in TAZ KO 
mitochondria. The maintenance of protein complexes indicated that core constituents 
were not dissociated from interaction partners. This finding was confirmed by 
coimmunprecipitation of TIM23 and TIM50. The interaction of both core components 
in TAZ KO MEF cells was not affected (Figure 3.13B).  
These approaches indicate, that tafazzin deficiency in MEF cells does not affect 




Figure 3.13: The protein levels and structural integrity of translocases are not affected in TAZ 
KO MEF mitochondria 
(A) Mitochondria from WT and TAZ KO MEF cells were isolated by differential centrifugation and 
separated on a 12,5% SDS-PAGE resolving gel. Indicated proteins were detected by immunoblotting.  
(B) Mitochondria from WT MEF cells were coimmunprecipitated by TIM23 and control antibody 
(control) in 1% digitonin-containing solubilization buffer. Samples were separated on 12,5% SDS-
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(C) WT and TAZ KO MEF mitochondria were separated by 2D-BN-SDS-PAGE analysis. Protein 
complexes were detected by western blotting against TIM50, TIM23 and COX6a 
 
 
3.4.2 MCU and EMRE are presequence-containing mitochondrial proteins 
 
The reorganized MCU complexes in TAZ KO MEF cells suggested, that the assembly 
of MCU complexes were affected. Therefore, the import and assembly pathway of 
MCU complexes via in-vitro import of 35S labeled MCU and EMRE precursors into 
isolated mitochondria was addressed. The precursors were translated from mRNA in 
reticulocyte lysates. Both, MCU (Figure 3.14A) and EMRE (Figure 3.14B) contained 
a mitochondrial presequence, which was cleaved after protein translocation into 
mitochondria. The presequence of MCU consisted of 50 amino acids (total weight: 39 
kDa and presequnce: 5 kDa) and EMRE contained a presequence of 4 kDa (total 
weight: 11 kDa). Newly synthetized MCU and EMRE preproteins were imported in a 
time-dependent manner. A cocktail of antimycin, valinomycin and oligomycin (AVO 
mix) dissipated the membrane potential, the driving force of mitochondrial import, 
thus acted as a negative control. The treatment of mitochondrial samples with 
proteinase K (PK) after import reactions showed that the cleaved and matured forms 
of MCU and EMRE were imported to PK-protected mitochondrial compartments. The 
non-imported precursors were degraded by PK treatment. The degradation products of 
the EMRE precursor covered the matured EMRE, so that EMRE import reactions in 
following chapters were performed without PK treatments.  
A protocol of in-vitro import reactions of MCU and EMRE precursors was 
extablished for further analysis of MCU assembly. 
 
Figure 3.14: Radiolabeled human [35S] MCU and [35S] EMRE preproteins contain a 
mitochondrial presequence, which is cleaved after in-vitro import into isolated mitochondria 
(A) [35S] MCU and (B) [35S] EMRE were imported into freshly prepared WT MEF mitochondria for 
depicted time points. Import reactions were stopped by membrane potential dissipation. Samples were 
treated with proteinase K (PK) where indicated. Import samples were analysed by SDS-PAGE 
analysis, additional western blotting and autoradiography. p, precursor; m, mature protein. 
 
3.4.3 Import of radiolabeled EMRE and motor-dependent import of OTC into 
MEF mitochondria is not affected by TAZ KO 
 
The mitochondrial precursor import pathway in purified TAZ KO MEF mitochondria 
can be tested by in-vitro import of newly synthezised mitochondrial precursors. The 
soluble mitochondrial protein ornithine transcarbamylase (OTC) has been used to 
examine if the motor- and TIM23-dependent protein translocation into TAZ KO 
mitochondria was affected. The import of newly synthetized radioactive OTC into 
isolated TAZ KO mitochondria was not changed (Figure 3.15A+B).  
The EMRE protein steady state levels were not affected in TAZ KO MEF cells 
(Figure 3.1). This observation could correlate with unaltered mitochondrial import of 
EMRE preproteins. Indeed, 35S labeled EMRE import into WT and TAZ KO MEF 
mitochondria were not affected (Figure 3.15C+D). 
In-vitro import of the mitochondrial preproteins EMRE and OTC is not altered in 
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Figure 3.15: In-vitro import of [35S] OTC from rat and human [35S] EMRE preproteins into 
isolated MEF mitochondria are not affected in TAZ KO 
(A) [35S] OTC and (C) [35S] EMRE were imported into freshly prepared WT and TAZ KO MEF 
mitochondria. Import reactions were stopped by membrane potential dissipation. Samples of [35S] OTC 
import were treated with proteinase K (PK). Import samples were analysed by SDS-PAGE analysis, 
additional western blotting and autoradiography 
(B) [35S] OTC and (D) [35S] EMRE imports were quantified densiometrically by ImageJ (n = 3, mean ± 
SEM). p, precursor; m, mature protein. 
 
3.4.4 Interaction of newly imported radioactive EMRE with MCU-FLAG is not 
affected in TAZ KO MEF mitochondria 
 
The in-vitro import of EMRE preprotein was unaffected in TAZ KO MEF 
mitochondria (Figure 3.15) and the assembly of newly imported EMRE into MCU 
complex was addressed. The interaction of in-vitro imported EMRE with MCU was 
investigated by coimmunoprecipitation (Co-IP) of radioactive, newly imported EMRE 
with FLAG-tagged MCU of MCU-FLAG-overexpressing WT and TAZ KO MEF 
mitochondria. EMRE precursors were imported for 30 minutes instead of 15 minutes 
to enable its insertion into the inner mitochonrial membrane and assembly with MCU. 
Afterwards, these mitochondria were solubilized by digitonin and were subjected to 
coimmunpreticipation with FLAG-tagged MCU. The input samples of the 
coimmunprecipitation confirmed that the EMRE import into WT and TAZ KO 
















     7    15  15   3
+ + + -














     7    15  15   3
+ + + -
 1 2 3 4 6 7 85
D
C
on SDS-PAGE. The eluate showed how much of imported EMRE was pulled down in 
WT and TAZ KO. The interaction of newly imported EMRE with MCU-FLAG 
revealed no differences between both genotypes. The other 50 % of the eluate were 
loaded on BN-PAGE to analyse, in which MCU-FLAG-containing complexes EMRE 
was assembled (Figure 3.16B). EMRE assembly into MCU underwent a ratio shift 
between WT and TAZ KO mitochondria. EMRE assembled more to the 1000 kDa 
MCU complex in WT mitochondria while the majority of EMRE in TAZ KO 
assembled with the the 500 kDa MCU complex. This observation confirmed the 
previous findings that MCU-EMRE complex organization was characterized by a 
ratio shift of MCU complexes in the kDa range (Figure 3.3) that the MCU-EMRE 
interaction was not affected in TAZ KO MEF cells (Figure 3.6). 
 
 
Figure 3.16: Interaction of newly imported [35S] EMRE with MCU is not altered in TAZ KO 
MEF cells  
(A) Human [35S] EMRE preproteins were imported into MCU-FLAG-containing WT and TAZ KO 
MEF mitochondria which were transfected with human MCU-FLAG plasmid three days before. 
Imports into freshly prepared WT and TAZ KO MEF mitochondria were conducted for 30 minutes. 
Import reactions were stopped by membrane potential dissipation. Mitochondria were solubilized by 
1% digitonin-containing buffer and coimmunprecipitated by FLAG beads. 50% of the native eluate 
was loaded on SDS-PAGE and (B) 50% to BN-PAGE analysis. [35S] EMRE import and assembly 
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3.4.5 In-vitro precursor import of radiolabeled MCU into isolated WT and TAZ 
KO MEF mitochondria  
 
In addition to the in vitro import and assembly of EMRE preproteins into MEF 
mitochondria, MCU precursor imports were established to study EMRE-MCU 
interaction. Therefore, the human MCU preproteins synthesized reticulocyte lysate 
were imported to WT and TAZ KO MEF mitochondria. Controversely, the amount of 
matured MCU in the TAZ KO import sample was decreased (Figure 3.17A+B).  
MCU protein steady state levels were unaltered (Figure 3.1). The time frame of the 
MCU import did not matter. The reduction of processed MCU in TAZ KO was 
observed in all time points. 
 
Figure 3.17: In-vitro import of [35S]MCU preproteins into isolated MEF mitochondria is affected 
in TAZ KO 
(A) Human [35S] MCU was imported into freshly prepared WT and TAZ KO MEF mitochondria. 
Import reactions were stopped by membrane potential dissipation. Import samples were analysed by 
SDS-PAGE analysis, additional western blotting and autoradiography. 
(B) [35S]MCU imports were quantified densiometrically by ImageJ (n = 3, mean ± SEM). p, precursor; 
m, mature protein. 
 
3.4.6 EMRE interaction with imported MCU is not affected in TAZ KO MEF 
cell mitochondria 
 
The levels of mature MCU after in-vitro import of MCU preprotein into TAZ KO 
MEF mitochondria were reduced (Figure 3.17). The effect of reduced mature MCU 
on assembly of newly imported EMRE into MCU complex was addressed. The 
interaction of newly imported MCU with endogenous EMRE in WT and TAZ KO 
mitochondria has been investigated by Co-IP. Radioactive labeled MCU was 
imported to isolated mitochondria for 30 minutes and solubilized by digitonin. MCU 
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samples of the EMRE antibody IP showed the import reactions as well (Figure 3.18A, 
lanes 4 and 5). The matured MCU was reduced in comparison to imported MCU in 
WT. The eluate samples revealed that endogenous, pulldowned EMRE interacted 
with imported MCU. The interaction of MCU and EMRE seemed to be reduced in 
TAZ KO, but the signal of matured/imported MCU in TAZ KO was reduced to the 
same degree (around 78%, Figure 3.18B). As a consequence, the amount of matured 
MCU in TAZ KO was decreased, so that MCU could just interact with endogenous 
EMRE in a lesser amount. Interaction of endogenous EMRE with imported 
radioactive MCU is not affected in TAZ KO MEF cell mitochondria. 
 
 
Figure 3.18: Interaction of newly imported [35S]MCU with endogenous EMRE is not altered in 
TAZ KO MEF cells  
(A) Human [35S]MCU preproteins were imported into WT and TAZ KO MEF mitochondria. Imports 
into freshly prepared WT and TAZ KO MEF mitochondria were performed for 45 minutes. Import 
reactions were stopped by membrane potential dissipation. Mitochondria were solubilized by 1% 
digitonin-containing buffer and coimmunprecipitated by EMRE co-immunpreticipation (Co-IP). 
Tafazzin antibody acted as negative control. Import and Co-IP samples were loaded and separated on 
10-18% gradient SDS-PAGE. [35S]MCU import and Co-IP samples were analysed by SDS-PAGE 
analysis, additional western blotting and autoradiography. p, precursor; m, mature protein. 
(B) Experiment was performed twice, quantified by ImageJ and showed the same result (n = 2). 
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The reduced amount of matured MCU in TAZ KO MEF mitochondria after in vitro 
import did not affect the EMRE-MCU interaction (Figure 3.18). Further analysis was 
required to investigate, why matured MCU was reduced. One possibility was a 
pulse/chase assay to investigate the turnover of imported MCU in WT and TAZ KO 
MEF mitochondria. 
The hypothesis was, that the turnover of imported MCU could have been decreased in 
TAZ KO. MCU was imported for 15 minutes and the reduction of processed MCU in 
TAZ KO mitochondria was observed (Figure 3.19A, lanes 2 and 7). The import 
reactions were stopped by dissipating the membrane potential via adding AVO mix. 
In the following hour, samples were taken at the depicted time points. The turnover of 
matured MCU in WT and TAZ KO was unaffected (Figure 3.19B). Figure 3.17 gave 
already an indication that the reduced processed MCU levels in TAZ KO did not 
depend on the import time frame. Longer import could provoke higher turnover of 
MCU in TAZ KO perhaps. However, MCU import after 3, 7 and 15 minutes were 
decreased in comparison to WT (Figure 3.17), so that the import time of 15 minutes 
was not too long.  
The degradation rate of newly imported, mature MCU is not altered in WT and TAZ 
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Figure 3.19: Turnover of newly imported [35S]MCU in TAZ KO MEF mitochondria is not 
affected 
(A) Human [35S]MCU preproteins were imported into WT and TAZ KO MEF mitochondria for 15 
minutes (Pulse). Import reactions were stopped by membrane potential dissipation. Single import 
samples were taken after 15, 30 and 45 minutes (Chase). Import samples were loaded and separated on 
12,5% SDS-PAGE resolving gels. Separated samples were blotted to PVDF membranes and exposed 
to phosphor screens (autoradiography). p, precursor; m, mature protein. 
(B) [35S]MCU import and turnover samples were quantified densiometrically by ImageJ (n = 3, mean ± 
SEM).  
 
3.4.8 Insertion of proteins containing 2 transmembrane domains (TMDs) is not 
affected in TAZ KO 
 
The MCU protein contains two transmembrane domains (TMDs) and insertion of 
both TMDs into the IMM was affected in TAZ KO mitochondria. This hypothesis 
was tested by an in-vitro import of yeast Pam17, which contains two TMDs as well. 
Pam17 import and maturation were not reduced in comparison to MCU import in 
TAZ KO. Mature Pam17 was even increased (Figure 3.20). Two-transmembrane 
domains did not seem to be the reason for the reduced amout of mature MCU in TAZ 
KO MEF mitochondria (Figure 3.17). 
 
 
Figure 3.20: In-vitro import of yeast [35S]Pam17 preproteins into isolated MEF mitochondria is 
not reduced in TAZ KO in comparison to imported, mature MCU 
Yeast [35S]Pam17 was imported into freshly prepared WT and TAZ KO MEF mitochondria. Import 
reactions were stopped by membrane potential dissipation. Import samples were analysed by SDS-
PAGE analysis, additional western blotting and autoradiography.  
The experiment was performed two times with the same result (n = 2) p, precursor; m, mature protein. 
 
3.4.9 Lack of MICU1 does not affect MCU in-vitro import 
 
Figure 3.7 indicated, that TAZ KO MEF mitochondria contain less MICU1 bound to 
the MCU pore. The MICU1 steady state levels were not reduced (Figure 3.1), but the 
MDa MCU complex (MCU-3) in TAZ KO was lacking. The reduction of one MCU 
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Therefore, MICU1 mRNA levels were silenced by specific siRNA for three days and 
MCU was imported into non-targeted and MICU1 knockdown MEF mitochondria 
(Figure 3.21). However, MICU1 knockdown did not affect MCU protein steady state 
levels or the in-vitro import of MCU.  
 
 
Figure 3.21: In-vitro import of [35S] MCU preproteins into Micu1-silenced MEF mitochondria is 
not affected 
(A) Human [35S] MCU was imported into freshly prepared non-target control (NT) and MICU1 
knockdown MEF mitochondria (siMICU1) 3 days after siRNA tranfection. Import reactions were 
stopped by membrane potential dissipation. Import samples were analysed by SDS-PAGE analysis, 
additional western blotting and autoradiography. 




3.4.10 Membrane potential sensitivity of MCU import in TAZ KO mitochondria 
 
Chowdhury et al. already published, that the membrane potential of TAZ KO MEF 
mitochondria is reduced (Chowdhury et al., 2018). The mitochondrial membrane 
potential is the driving force of mitochondrial preprotein import. Decreased amount of 
membrane potential could impact the protein import in general or only for single 
precursors. Figure 3.15 has already shown, that EMRE and OTC import into TAZ KO 
MEF mitochondria was not reduced. Hence, the dampened membrane potential in 
TAZ KO MEF mitochondria did not affect the mitochondrial protein translocation of 
these two preproteins. However, the possibility was addressed, if mitochondrial 
import of MCU preprotein was more sensitive to the reduced membrane potential in 
TAZ KO MEF mitochondria (Figure 3.22). Therefore, radiolabeled MCU precursor 
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chlorphenylhydrazon). Final CCCP concentrations in mitochondria were titrated from 
0 to 400 nM. MCU precursor was added to every single import reaction 3 minutes 
after adding CCCP. The motor-dependent OTC import was not affected TAZ KO 
MEF mitochondria (Figure 3.22A, lanes 2 and 8). Upon increasing CCCP 
concentrations, OTC import was reduced (Figure 3.22B). Interestingly, MCU 
preproteins could just imported upon 50 nM CCCP, indicating that MCU import 
could require more membrane potential to be translocated to its mitochondrial 
localization. The direct comparison of OTC and MCU imports into CCCP-treated WT 
and TAZ KO mitochondria was performed once (Figure 3.22A). However, the 
comparison of radioactive OTC and MCU imports into CCCP-treated WT 
mitochondria was performed several times and was quantified. The reduced MCU 
import into membrane potential depleted mitochondria was statistically relevant 
(Figure 3.22B). The reduced amount of mature MCU could be explained by reduced 




Figure 3.22: In-vitro import of [35S] MCU preproteins is membrane potential sensitive in 
comparison to [35S] OTC import into WT MEF mitochondria 
(A) Human [35S] MCU and rat [35S] OTC were imported into freshly prepared WT and TAZ KO MEF 
mitochondria for 15 minutes. 3 minutes, before starting each import reaction, CCCP (Carbonylcyanid-
m-chlorphenylhydrazon) in the indicated concnetrations was added. Import reactions were stopped by 
membrane potential dissipation. Import samples were analysed by SDS-PAGE analysis, additional 
western blotting and autoradiography. 
p, precursor; m, mature protein. 
(B) The comparison of [35S] MCU and [35S] OTC import into WT cells was performed three times and 
was quantified by ImageJ (n = 3, mean ± SEM). 
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3.5.1 MCU complexes are tissue-specifically organized 
 
The finding of altered MCU complex organization in TAZ KO MEF cells brought up 
the question, how MCU complexes are composed or organized in other taffazin-
deficient model systems, such as organs from the ROSA26 shTAZ mouse (Barth 
Syndrome (BTHS) mouse). The tafazzin silencing in the BTHS mouse was caused by 
a conditional doxycyclin-dependent shTAZ expression.  
To address the MCU complex organization in mouse organs, isolated mitochondria 
from different tissues were solubilized in a 1% digitonin-containing solution and 
separated on BN-PAGE in the first and on SDS-PAGE in the second dimension. 
Figure 3.23 displays the direct comparison of the migration pattern of MCU 
complexes in WT/TAZ KO MEF cells, WT/BTHS mouse skeletal muscle, WT liver 
and WT brain (Figure 3.23). The ratio shift of the 1 MDa (MCU-2, lane 2) and 500 
kDa (MCU-3, lane 2) MCU complexes in MEF cells were observed for WT and 
BTHS skeletal muscle MCU as well. After BN-PAGE separation MCU from skeletal 
muscle and MEF cells displayed the same migration pattern in both genotypes, 
respectively. MEF cell mitochondria contained the higher MDa MCU complex 
(MCU-1, lane 2), which was not present in skeletal muscle cells. The migration 
pattern of mouse skeletal muscle and MEF MCU complexes on BN-PAGE differ 
from the migration pattern of mouse liver and brain MCU. The predominant MCU 
form in mouse liver migrated at 400 kDa and was smaller than the WT MCU 
complexes in MEF cells and skeletal muscle. In contrast, WT mouse brain MCU 
complexes occured in the MDa range, predominantly (Figure 3.23).  
The direct comparison of separated MCU complexes displayed, that MCU complexes 
are differently organized in mouse organs. 
 
 
Figure 3.23: MCU complex organization is tissue- and cell type-specific. 
Mitochondria isolated from WT and BTHS mouse liver, brain, skeletal muscle and MEF cells were 
solubilized by 1% digitonin-containing buffer and resolved by 2D-BN-SDS-PAGE analysis. Protein 
complexes were detected by immunoblotting against MCU and ATP5B  
 
3.5.2 Protein steady state levels of respiratory chain components and MCU in 
mouse skeletal muscle 
 
Respiratory chain and MCU steady state levels in BTHS mouse skeletal muscle 
mitochondria were characterized. It is already known, that complex II levels are 
reduced and the respiratory chain complexes are remodeled in BTHS mouse hearts 
(Dudek et al., 2016). These findings were cardiac specific and were not found in liver 
or kidney. The protein steady state levels of CI, CIII, CIV and CV components were 
not affected in BTHS mouse hearts and patient-derived iPSC cardiomyocytes (Dudek 
et al., 2016). Thus, we monitored, if protein levels of the respiratory chain showed 
alterations in BTHS mouse skeletal muscle. A deeper look into the protein levels of 
mitochondrial proteins COX1, RIESKE and ATP5B (Figure 3.24A) showed, that 
tafazzin deficiency in mouse skeletal muscle did not alter the protein abundance of 
these core constituents. Figure 3.24B displays, that respiratory chain complexes were 
reorganized, which was already shown in BTHS cardiomyocytes (Dudek et al., 2016). 
CII (SDHA decoration) was not significantly reduced in BTHS skeletal muscle in 
comparison to BTHS mouse hearts. Respirasomes in BTHS skeletal muscle were 





















from other BTHS models (Dudek et al., 2016). Interestingly, MCU and its interaction 
partner EMRE were slightly reduced in BTHS skeletal muscle mitochondria.  
 
 
Figure 3.24: MCU and respiratory chain protein steady state levels in BTHS mouse skeletal 
muscle 
(A) Mitochondria from WT and BTHS mouse skeletal muscle were isolated by differential 
centrifugation and separated on a 12,5% SDS-PAGE resolving gel. Indicated proteins were detected by 
immunoblotting (n = 2) 
(B) Mitochondria from WT and BTHS mouse skeletal muscle were solubilized by 1% digitonin and 
separated on BN-PAGE resolving gel (4-13%). Protein complexes were detected by immunoblotting 
against SDHA, NDUFB8, Rieske and ATP5B 
 
3.5.3 MCU/EMRE interaction in BTHS mouse skeletal muscle is unaffected 
 
The MCU complex ratio shifts in TAZ KO MEF cells and BTHS mouse skeletal 
muscle showed similarity in the migration pattern after 2D-BN-SDS-PAGE analysis. 
Furthermore, the comigration and interaction studies of MCU and EMRE in MEF 
cells have shown, that the MCU/EMRE interaction and steady state levels were 
unaffected in TAZ KO MEF cells. The interaction of MCU and EMRE in BTHS 
mouse skeletal muscle was addressed by coimmunprecipitation. MCU complexes 
comigrated with EMRE after 2D-BN-SDS-PAGE analysis (Figure 3.25A). MCU was 
pulled down by an EMRE antibody conjugated to protein-A sepharose (Figure 
3.25B). The input of applied native lysates from WT and BTHS skeletal muscle 
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in comparison to WT (Figure 3.25C, lanes 2 and 3). The levels of pulldowned MCU 
in BTHS (eluate) were decreased to the same extent as in the input (Figure 3.25C, 
lanes 5 and 6).  
These results go along with the findings in MEF cells, that the integral MCU/EMRE 
module stays stable independently from tafazzin. MCU complexes in mouse skeletal 
muscle contain EMRE and the MCU/EMRE interaction in BTHS mouse skeletal 





Figure 3.25: Lack of tafazzin causes reorganization of MCU complexes in mouse skeletal muscle, 
but does not affect MCU-EMRE interaction 
(A) Mitochondria from WT and BTHS mouse skeletal muscle were solubilized by 1% digitonin and 
separated by 2D-BN-SDS-PAGE analysis. Indicated proteins were detected by immunoblotting.  
(B) Mitochondria from WT and BTHS skeletal muscle were coimmunprecipitated by EMRE and 
tafazzin antibodies conjugated to protein A sepharose. Samples probed on SDS-PAGE were 
immunoblotted against EMRE, MCU and ATP5B 
(C) Experiment (B) was quantified densiometrically by ImageJ (n = 1), MCU bands in lanes 5 and 6 
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3.5.4 MCU and respiratory chain complexes in BTHS mouse brain are 
dissociated 
 
The composition of mouse brain MCU complexes and respiratory chain complex 
organization was investigated. MCU complexes and comigration of the interaction 
partner EMRE were detected after a subsequent second-dimensional run on SDS-
PAGE (Figure 3.26A). WT mouse brains express two major MCU-containing 
complexes in the MDa range (complexes MCU-1 and MCU-2), which are comparable 
to the MCU complex organisation in MEF cells (Figure 3.23). Both MCU-containing 
complexes comigrated with EMRE. MCU complexes in BTHS mouse brain 
underwent a ratio shift from the higher to the lower molecular weight forms. The 
MCU-1 oligomer was reduced and the MCU-2 complex became the more dominant 
form in BTHS brain. In addition, a lower molecular weight form of MCU at 500 kDa 
(MCU-3) became more prominent (Figure 3.26A).  
Mitochondria from WT and BTHS mouse brain were isolated and solubilized in 1% 
digitonin-containing buffer. Respiratory chain complexes were separated and 
visualized by BN-PAGE analysis in the first dimension (Figure 3.26B). 
The respiratory chain complexes revealed a similar phenotype regarding the 
abundence of higher molecular weight forms in the MDa range. The respirasomes in 
BTHS brain mitochondria were reduced in comparison to WT. Particularly, CIV 
constituent COX6a resided in smaller CIV oligomers predominantly and much lesser 
in respiratory chain supercomplexes. The CIII dimer remained stabil in BTHS and CI-
and CIII-containing complexes comigrated (Figure 3.26B). Beside the alterations of 
OXPHOS complex organisation in BTHS brain mitochondria, the carrier translocase 
TIM22 and the metabolite- and ion-conducting pore VDAC3 were slightly reduced in 




Figure 3.26: Lack of tafazzin causes reorganization of MCU and respiratory chain complexes 
(A) Mitochondria from WT and BTHS mouse brains were solubilized by 1% digitonin and separated 
by 2D-BN-SDS-PAGE analysis. Indicated proteins were detected by immunoblotting.  
(B) Mitochondria from WT and BTHS mouse brains were solubilized by 1% digitonin and separated 
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3.5.5 Tafazzin-deficiency does not affect MCU complex organization in BTHS 
mouse liver 
 
Figure 3.23 displayed, that MCU complexes undergo different organ-specific 
organizations. The MCU complex organization in WT and BTHS mouse liver was 
addressed. The predominant MCU complex in mouse liver mitochondria migrated at 
400 kDa in 2D-BN-SDS-PAGE analysis (Figure 3.27). Figures 3.3, 3.25, 3.26 
revealed that higher molecular weight forms of MCU were more abundant in MEF 
cells, mouse brain and skeletal muscle. Possibly, the liver-specific cardiolipin species 
pool and metabolic demands define this phenotype. The lack of tafazzin expression 
did not seem to affect the stability of 400 - 500 kDa MCU complexes in general, 
which was shown by the stability of the 500 kDa MCU complexes in diverse BTHS 
models (Figures 3.3, 3.25, 3.26). This observation could explain that liver MCU 
complex integrity was not dependent on tafazzin activity. MCU complex steady state 
levels and organization were not affected in BTHS mouse liver. 
 
Figure 3.27: MCU complex organization in BTHS mouse liver is not affected 
Mitochondria isolated from WT and BTHS mouse liver were solubilized by 1% digitonin-containing 
buffer and resolved by 2D-BN-SDS-PAGE analysis. Protein complexes were detected by 
immunoblotting against MCU and ATP5B  
 
3.5.6.1 MCU protein steady state levels are reduced in mitochondria of BTHS 
mouse hearts  
 
BTHS mouse brain, skeletal muscle and TAZ KO MEF mitochondria showed 
















in skeletal muscle were slightly reduced, but still abundant (Figure 3.24). The steady 
state levels of WT and BTHS mouse hearts were considered. Figure 3.28A displays 
the reduction of MCU protein levels in cardiac BTHS mitochondria. Mitochondria 
from 4 different WT and BTHS mice were isolated and the MCU protein levels were 
compared after SDS-PAGE separation. MCU levels were reduced in BTHS mice. The 
reduction or even loss of MCU could have consequences for cellular calcium 
homeostasis. Unpublished data indicated that mitochondrial calcium uptake into 
BTHS cardiomyocytes were depleted caused by the lack of MCU (Dudek, Maack et. 
al., unpublished). In addition, MCU mRNA levels in BTHS mouse hearts were not 
diminished (Rehling and Maack, unpublished).  
The reduction of cardiac MCU in BTHS mice was compared to MCU steady state 
levels in both, mouse liver and brain. Both organs conduct relevant metabolic 
functions like heart and skeletal muscle. However, the MCU protein steady state 
levels in these organs were not decreased in BTHS mouse (Figure 3.28B). As a result, 




Figure 3.28: Reduction of MCU steady state levels in BTHS mouse hearts is not observed in liver 
and brain 
(A) Cardiac mitochondria from four different WT and BTHS mice pairs were isolated by differential 
centrifugation and separated on a 12,5% SDS-PAGE resolving gel. Indicated proteins were detected by 
immunoblotting.  
(B) Brain, liver and heart of a WT and BTHS mouse pair were dissected and mitochondria were 
isolated. Samples were separated on 12,5% SDS-PAGE running gel and immunoblotted against 
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3.5.6.2 Steady state levels of MCU complexes are reduced in mitochondria of 
BTHS mouse hearts and BTHS patient derived cardiomyocytes 
 
To address to which extent the reduction of MCU in BTHS mouse hearts affect the 
steady state levels of MCU complexes, MCU/EMRE-containing complexes were 
separated via 1D- and 2D-BN-SDS-PAGE analysis. The loss of the MCU protein as 
one core component of the uniporter caused the loss of the total complex (Figure 
3.29A). Reduced cardiac MCU complexes in BTHS did not show any indications for 
MDa complex dissociation or remodeling in comparison to the MCU complex ratio 
shifts in MEF TAZ KO cells, BTHS mouse skeletal muscle and brain. Furthermore, 
the respiratory chain complexes (here indicated as COX1/CIV decoration) were 
reorganized and respirasomes were reduced.  
Further protein steady state levels of mitochondrial proteins in cardiac tissues were 
examined (Figure 3.30B). Respiratory chain components NDUFB8 (CI), RIESKE 
(CIII), COX4I1/2, COX6a (CIV) and ATP5B (CV) were not affected in BTHS mouse 
hearts as already published (Dudek et al., 2016). The levels of translocase constituents 
Tim22 and Tim50 were not altered, but LON protease 1 (LONP1) was increased in 
BTHS hearts. LONP1 participates in mitochondrial stress response and protein quality 
control (Li et al., 2019). Beside the reduction of MCU levels in BTHS 
cardiomyocytes (Figure 3.28), its interaction partners EMRE and MICU1 were 
slightly decreased as well, but not to the extent of the MCU reduction.  
The reduction of MCU steady state levels in BTHS mouse hearts was also found in 
BTHS patient-derived induced pluripotent stem cell cardiomyocytes (iPSC 




Figure 3.29: MCU protein steady state levels are reduced in BTHS mouse heart mitochondria 
(A) Mitochondria from WT and BTHS mouse mitochondria were isolated by differential centrifugation 
and separated on a 12,5% SDS-PAGE resolving gel. Indicated proteins were detected by 
immunoblotting.  
(B) WT and BTHS mouse heart mitochodria were solubilized by 1% digitonin and separated on BN-
PAGE resolving gel (4-13%). For detection of EMRE, single BN-PAGE lane was additionally 
separated in the second denaturing condition. Protein complexes were detected by immunoblotting 
against COX1, MCU, EMRE and ATP5B 
(C) Steady state levels of MCU and ATP5B from BTHS patient-derived induced pluripotent stem cell 
cardiomyocytes (iPSC cardiomyocytes). Separation on 12,5 % SDS-PAGE and western blotting 
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4. Discussion 
 
4.1 MCU complex organization in BTHS models 
 
The comparison of separated MCU complexes after 2D-BN-SDS-PAGE analysis of 
mouse organs displayed, that the migration patterns of MCU complexes differ in the 
observed organs (Figure 3.24). Liver, brain, skeletal muscle and heart are 
metabolically important organs, which differ in their involvement of calcium 
signaling in metabolic pathways and cellular processes (Paillard et al., 2017; Wescott 
et al., 2019). The direct comparison of MCU complex sizes among mouse organs 
showed that liver MCU complex distribution varies from the other organs in the size 
of the smallest detectable MCU complex and the complex organization (Figure 3.28). 
The predominant form of MCU in mouse liver is a 400 kDa complex. In contrast, the 
smallest detectable form of MCU in mouse skeletal muscle, heart, brain and MEF 
cells is a 500 kDa MCU complex (MCU-3). The reason for this size difference of 
MCU complexes between liver (400 kDa) and of the other organs (500 kDa) could 
not be clarified in this study. The presumable lack of one MCU component in liver 
MCU complex could cause the size difference between 500 kDa and 400 kDa. The 
known MCU constituents (MCU, MCUR1, MCUb, MICU1/2) have a molecular 
weight ranging from 34 to 50 kDa. The lack of one of these components could explain 
the size shift. MCU protomers are organized as tetramers forming the calcium-
conducting pore (Baradaran et al., 2018; Fan et al., 2018; Oxenoid et al., 2016; Yoo et 
al., 2018). Therefore, two to four monomers of the known MCU interaction partners 
(MCUR1, MCUb, MICU1/2) would cover a size difference of 100 kDa between a 400 
and a 500 kDa complex. For instance, it has been shown, that MCUb interacts with 
each MCU protomer in WT mammalian cells (Lambert et al., 2020). The same 
finding was made for MCU-EMRE interaction. Each MCU protomer of the MCU 
pore interacts with one single EMRE (Wang et al., 2019). The stoichiometry of MCU 
to other interaction partners can change from organ to organ (Paillard et al., 2017) and 
also depends on the physiological environment (Lambert et al., 2019). For instance, 
the MCU-to-MCUb ratio is relatively high in skeletal muscle and is reduced in 
cardiac tissues (Paillard et al., 2017). Another example of adapting MCU complex 
compositions is the MCUb-to-MCU ratio during cardiac failure. MCU and the 
gatekeepers MICU1 and MICU2 are displaced by MCUb in cardiac injury, to prevent 
calcium overload into cardiac mitochondria. This stress responsive mechanism has the 
consequence that the MCU complex size is lowered because of lacking gatekeepers, 
which can interact with MCU, but not with MCUb (Lambert et al., 2019).  
Those considerations about adapting ratios of MCU to MCU interaction partners 
show that the MCU complex composition underlies a basic tetrameric structure, but 
the incorporation or release of MCU interaction partners go along with cellular and 
mitochondrial requirements. Our work confirms, that MCU-EMRE complex 
organization is tissue-specific. 
 
4.2. Increased basal mitochondrial calcium uptake and the role of MICU1 in 
TAZ KO MEF cells 
 
The investigation of MCU complexes in BTHS mouse brain, skeletal muscle and 
TAZ KO MEF cells showed, that the integrity of higher-order MCU complexes 
depends on cardiolipin (Figure 3.3). To understand the physiological relevance of 
altered MCU complex organization on the mitochondrial calcium homeostasis, the 
role of MCU gatekeepers MICU1 and MICU2 was addressed. The MCU constituents 
MICU1 and MICU2 play a crucial role in the regulation of MCU activity (Csordas et 
al., 2013; Mallilankaraman et al., 2012; Patron et al., 2014; Petrungaro et al., 2015). 
The loss of MCU gatekeeping function can result in mitochondrial calcium overload 
and mitochondrial permeability transition pore (MPTP) opening (Antony et al., 2016; 
Logan et al., 2014; Mallilankaraman et al., 2012; Patron et al., 2014). MCU-EMRE 
complexes of neuronal mitochondria, lacking MICU1/2 show increased mitochondrial 
calcium uptake and vulnerability to calcium overload leading to neuronal death 
(König et al., 2016). The results of this work show, that MCU complex organization 
in TAZ KO MEF cells and BTHS mouse brain and skeletal muscle is altered. The 
ratio of MCU complexes in the MDa range to MCU complexes in the kDa range is 
shifted to the kDa range in mitochondria from TAZ KO MEF cells and BTHS mouse 
skeletal muscle and brain (Figure 3.3, Figure 3.23, Figure 3.26). MCU complexes in 
MEF cells appear in three different molecular weight forms, called MCU-1 (> 2 
MDa), MCU-2 (1 MDa) and MCU-3 (500 kDa) (Figure 3.3). All MCU complexes 
consist of the integral membrane protein EMRE, an integral membrane protein, which 
interacts with the MCU pore-forming subunit and is essential to uptake cellular 
calcium into mitochondria of mammalian cells (Tsai et al., 2017). The gatekeeping 
subunit MICU1 was detected only in the MCU-1 complex by depletion of a MICU1-
containing MCU complex via coimmunprecipitation (Figure 3.7). The MCU-1 
complex is absent in TAZ KO MEF cells, which might have physiological 
consequences for the cellular, or at least, the mitochondrial calcium homeostasis. 
Measurements of mitochondrial calcium uptake in WT and TAZ KO MEF cells 
displayed that the basal mitochondrial calcium uptake is increased in TAZ KO MEF 
mitochondria (Figure 3.12). The co-ocurrence of elevated basal mitochondrial 
calcium uptake and MICU1-lacking MCU complexes was observed in previous 
studies (König et al., 2016; Petrungaro et al., 2015). If the concentration of cellular 
calcium increases beyond a threshold concentration (0,1 - 1 µM approximately), 
binding of calcium to MICU subunits initiate the MCU pore opening and calcium 
conductance into mitochondria (Figure 4.1) (Kamer et al., 2017; Liu et al., 2016; 
Paillard et al., 2018). MICU1-lacking MCU complexes are constitutively active and 
mitochondrial calcium uptake is not regulated under these conditions (König et al., 
2016; Petrungaro et al., 2015). MICU1-lacking MCU complexes in TAZ KO MEF 
cells could cause unregulated and increased basal mitochondrial calcium uptake in our 
study. This was considered as an initial working model, but missing information 
about the further composition of MCU complexes in MEF cells did not allow a 
statement on the causality between the MCU complex ratio shifts and the increased 
basal calcium levels in TAZ KO MEF cells. The identification of MCUb- and 
MCUR1-containing MCU complexes was not successful in this study. MCUb is 
discussed to inhibit MCU activity (Raffaello et al., 2013; Lambert et al., 2019; 
Paillard et al., 2017), whereas MCUR1 is a regulator of MCU required for 
mitochondrial calcium uptake (Adlakha et al., 2019; Mallilankaraman et al., 2012, 
2015; Tomar et al., 2016; Vais et al., 2015). Both MCU subunits or additional 
unknown MCU components could cause the observed increased mitochondrial 
calcium levels in TAZ KO MEF cells.  
Conclusively our hypothesis is, that the lack of tafazzin in BTHS mouse models 
causes the assembly and stability defect of MICU1-containing MCU complexes. 
Therefore, unregulated MCU-EMRE complexes are constitutively active and basal 
uptake of cytosolic calcium into mitochondria is increased. 
 
 
Figure 4.1: Proposed mitochondrial calcium uptake in WT and TAZ KO MEF cells  
The concentration of cytosolic calcium increases beyond a threshold concentration and binding of 
calcium to MICU subunits can initiate calcium conductance into mitochondria via MCU pore opening. 
The model suggests, that less gatekeeping of MCU activity causes a constitutively active MCU-EMRE 
complex, which enables increased basal mitochondrial calcium uptake in TAZ KO MEF cells.  
 
 
4.3 MCU complex formation and role of reactive oxygen species (ROS) 
 
This work focused on how the lack of taffazin affects MCU complex organization. 
Protein-lipid interactions may maintain the structural integrity of MCU oligomers. In 
comparison to respiratory chain complexes (Sedlak and Robinson, 1999), stabilizing 
protein-cardiolipin interfaces in MCU are not known. MCU and respiratory chain 
complex integrity depend on cardiolipin remodeling (Figure 3.9). Putative MCU-
cardiolipin interfaces might affect the assembly and stability of MCU complexes. 
MCU complex assembly and organization could also be regulated by posttranslational 
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Calcium signaling and oxidative stress often act together to maintain cellular 
functions. The main source of ATP production is oxidative phosphorylation, but 
respiratory performance always holds the risk of increased reactive oxygen species 
(ROS) production. Production of mitochondrial ROS takes place in the respiratory 
chain and could cause cell damage, but is essential for regulatory functions as well 
(Brookes et al., 2004, Hamanaka and Chandel, 2010, Kiselyov and Muallem, 2016). 
Respiratory chain supercomplex formation (Figures 3.27, 3.30) and functions are 
impaired in Barth Syndrome models. Supercomplex formation is suggested to 
increase the efficiency of the electron transport within the respiratory chain and is 
proposed to reduce formation of ROS (Actin-Perez et al, 2008). ROS production is 
increased in BTHS mouse hearts and BTHS patient-derived induced pluripotent 
cardiomyocytes (iPSCs) (Dudek et al., 2016). It can be speculated, that ROS 
production and accumulation over life-time contributes to the pathophysiology of the 
BTHS mouse heart. The role of ROS damage and signaling in Barth Syndrome 
disease development remains still unclear. Beside the Barth Syndrome, it has been 
shown that increased ROS production could activate mitochondrial calcium uptake 
via MCU regulation (Dong et al., 2017). MCU undergoes several posttranslational 
modifications, which could affect its activity and its oligomerization state. It has been 
observed, that the N-terminal domain of MCU (MCU-NTD) contains a conserved 
cysteine (Cys-97), which could even act as a redox sensor. Oxidized Cys-97 
undergoes S-glutathionylation upon oxidative stress. Fast protein liquid 
chromatography (FLPC) analysis showed, that oxidation or mutation of Cys-97 could 
promote oligomerization of a 450-600 kDa MCU complex in HEK and Hela cells. 
Modification of Cys-97 revealed higher mitochondrial calcium uptake through MCU 
pore (Dong et al., 2017). The human 450-600 kDa MCU complex resolved by FLPC 
analysis reminds of the 400/500 kDa MCU complexes in mouse organs and MEF 
cells (MCU-3, Figure 3.2, 3.24). This complex may be the smallest member of MCU 
complex oligomers allowing regulated mitochondrial calcium uptake in mammalian 
cells. The observation of redox-dependent MCU oligomerization via FLPC analysis 
by Dong et al., 2017 initiated to address the role of ROS in MCU complex 
organization by BN-PAGE analysis (Figure 3.11). ROS quenching by Mitotempo 
could reduce the elevated ROS levels in TAZ KO MEF cells, but the reduction of 
mitochondrial ROS production could not show alterations in MCU oligomerization 
after 2-BN-SDS-PAGE analysis. Beside redox-dependent regulation of the MCU 
protein, it was quite obvious that the redox status of the intermembrane space could 
affect the redox-dependent MICU1 and MICU2 dimerization (Petrungaro et al., 
2015). Shifts in the redox state of the MICU gatekeepers from WT to TAZ KO MEF 
cells should also affect the MCU complex organization. Figure 3.1 showed, that the 
protein steady state levels of reduced MICU1 and MICU2 (total amounts) are not 
altered in TAZ KO. MICU1 and MICU2 protein levels on a non-reducing SDS-PAGE 
were also examined, but have not shown any differences in the levels of MICU 
monomers (reduced form) to MICU dimers (oxidized form) (Data not shown). Thus, a 
redox ratio shift of MICU1 and MICU2 has not been observed, which would affect 
MCU complex assembly in TAZ KO MEF mitochondria.  
Conclusively, this work has not shown an effect of ROS on MCU complex 
organization. 
 
4.4 Role of cardiolipin on MCU and respiratory chain complexes in cardiac 
tissues 
 
90% of metabolic energy in cardiomyocytes are provided by the mitochondrial 
respiratory chain. Fatty acids are the main carbon source under physiological 
conditions, which explains the high oxygen demand enabling fatty acid catabolism 
(Grynberg and Demaison, 1996). Cardiac fatty acid catabolism is coupled to the 
further oxidation of reducing equivalents the respiratory chain. Respiratory chain 
complexes are organized to supercomplexes/respirasomes composed of complex I, 
complex III and complex IV in mammalian cells (Althoff et al., 2011; Schägger and 
Pfeiffer, 2000). Cardiolipin enables the stabilization of every single respiratory chain 
complex and is required for their enzymatic activity. Additionally, stabilization and 
function of respiratory chain supercomplexes are dependent on cardiolipin (Bazan et 
al., 2012; Eble et al., 1990; Sharpley et al., 2006). Thus, defect in cardiolipin 
maturation in cardiomyocytes affects respiratory chain activity and stability of 
complexes. The Barth Syndrome (BTHS) is caused by impaired remodeling of 
cardiolipin by its acyltranferase tafazzin. The tafazzin deficiency in BTHS models 
displays different organ-specific phenotypes. Respiratory chain and MCU complexes 
in isolated mitochondria from BTHS mouse livers do not show differences in the 
organization of the observed oligomeric states of mitochondrial protein complexes 
(Figure 3.28, Dudek et al., 2016). Instead, cardiac respiratory chain supercomplexes 
are dissociated and respiratory chain is remodeled (Figure 3.30, Dudek et al., 2016). 
This study reveals that MCU protein steady state levels in BTHS mouse hearts are 
significantly reduced (Figure 3.29). MCU and EMRE containing complexes in BTHS 
mouse hearts are reduced, but they are not differently organized or display a ratio shift 
of higher to lower molecular weight forms from WT to BTHS (Figure 3.30). Instead, 
MCU complexes from TAZ KO MEF cells, BTHS mouse brain and skeletal muscle 
show the phenotype of dissociated MDa MCU complexes and a reorganized 
distribution of the MCU protein from MDa to kDa MCU complexes. The cardiac 
specificity of remodeled respiratory chain in comparison to kidney and liver and the 
reduction of MCU complexes in BTHS mouse hearts were explained by a cardiac-
specific cardiolipin species (Dudek et al., 2018). The predominant cardiolipin (CL) 
species in the heart is tetra-linoleoyl-CL (CL 72:8). Lack of tafazzin causes an 
increase of the precursor monolysocardiolipin (MLCL) in all mouse tissues, but the 
cardiolipin pools in various mouse organs are different. It is still unknown in general, 
which cardiolipin species promote protein complex stability or how cardiolipin 
species are distributed over respirasomes, translocases, and other mitochondrial 
protein complexes. In addition, it is not documented, how accumulated MLCL in 
BTHS models affect protein complex stability. However, the symptoms of the human 
BTHS disease show that cardiolipin deficiency is more deleterious in cardiac tissues 
as in other organs. For instance, the heart contains cardiac-specific isoforms of 
respiratory chain constituents (Grossman and Lomax, 1997). COX4a is a cardiac-
specific and cardiolipin-dependent subunit of complex VI and applies regulatory 
functions (Dudek et al., 2016). Perhaps, the cardiac tissue-specificity of cardiolipin 
species could explain the drastic reduction of MCU protein steady state levels in 
BTHS mouse hearts (Figure 3.29). Complex II deficiency was observed in BTHS 
mouse hearts and BTHS patient-derived iPSC cardiomyocytes (Dudek et al., 2016). 
The absence of protein complexes in cardiac BTHS mouse mitochondria could refer 
to an import defect of one of its subunits or an increased turnover of one of the 
complex constituents. The following chapter focuses on these two possibilities to 
explain the absence of protein complexes in BTHS mouse hearts. 
 
4.5 Mitochondrial import and stability of MCU precursor protein 
 
MCU and SDHA steady state levels in mitochondria from BTHS mouse hearts are 
reduced (Figure 3.28; Dudek et al., 2016). The reduction of both mitochondrial 
proteins might underlie the same cardiolipin-dependent mechanism. The precursor 
import of selected mitochondrial proteins could be affected in BTHS mouse hearts. 
In-vitro preprotein imports of MCU and the complex II subunit SDHA into purified 
mouse heart mitochondria could not be established. The in-vitro import of MCU was 
established in purified WT and TAZ KO MEF mitochondria (Figure 3.14). The in-
vitro import of MCU preprotein into MEF TAZ KO MEF mitochondria displays 
reduced mature MCU (Figure 3.17), whereas the MCU protein steady state levels are 
unaffected in TAZ KO MEF cells (Figure 3.1). In fact, the precursor import 
machinery (Figure 3.13) and the in-vitro import of the mitochondrial control 
preproteins EMRE and OTC are unaffected in TAZ KO MEF mitochondria (Figure 
3.15). In-vitro import of MCU preprotein into purified CCCP-treated mitochondria 
displays that the MCU import is more sensitive to reduced membrane potential than 
the import of the control precursor OTC (Figure 3.22). The impaired import of MCU 
preprotein into MEF TAZ KO mitochondria and the reduced MCU levels in BTHS 
mouse hearts might underlie the same taffazin-dependent mechanism. In this scenario, 
TAZ KO MEF cells are capable to compensate the impaired MCU import and MCU 
protein steady state levels are not reduced. Instead, reduced MCU levels in BTHS 
mouse heart mitochondria are not compensated. The second speculation for reduced 
MCU in BTHS mouse hearts is accelerated turnover of the MCU protein. Turnover 
assays of endogenous MCU in iWT and iTAZ iPSC cardiomyocytes have not 
clarified yet, if newly translated MCU degrades faster in iTAZ iPSC cardiomyocytes 
than in WT iPSC cardiomyocytes. The pulse-chase assay of newly imported MCU 
precursor into purified WT and TAZ KO MEF mitochondria indicates, that MCU 
does not degrade faster in mitochondria lacking taffazin (Figure 3.20). In general, the 
MCU protein is more stable, whereas EMRE degrades within 4 hours after inhibition 
of cytosolic translation (Tsai et al., 2017). The half-life of the MCU protein is more 
than 24 hours, whereas MICU1 has a half-life of approximately 5 hours (Petrungaro 
et al., 2015).  
Conclusively, in-vitro import of MCU precursors into TAZ KO MEF mitochondria 
displays reduced mature MCU, but not an increased turnover rate of newly imported 
MCU. It is speculative, if these findings in TAZ KO MEF cells can explain the 
observed phenotype of reduced MCU in BTHS mouse hearts. 
5. Conclusion of results 
 
This work has shown that WT MEF cells contain 3 different molecular weight forms 
of MCU, which undergo a complex ratio shift from WT to TAZ KO MEF 
mitochondria (Figure 3.4). The MCU complex ratio shift is specifically dependent on 
the phospholipid composition of mitochondrial membranes and not on regulation by 
ROS or other stimuli (Figure 3.11). The tafazzin complementation of TAZ KO MEF 
cells has shown that remodeled cardiolipin is required for the structural integrity of 
MCU complexes in the MDa range, but MCU oligomers with a size of 400-500 kDa 
do not require sufficient cardiolipin synthesis and remodeling (Figure 3.11). The 
MCU protein is distributed approximately 60% to the 1000 kDa (MCU-2) and 40% to 
the 500 kDa (MCU-3) form, whereas 90% of the MCU protein is distributed to the 
500 kDa form in TAZ KO MEF cells (Figure 3.12). The composition of those MCU 
complexes could not be solved completely in this study. The MICU gatekeepers 
reside in the higher MDa MCU complex (Figure 3.7), whereas information about the 
published MCU interaction partners MCUb and MCUR1 could not be provided. 
However, EMRE always interacts with the MCU pore-forming subunit, no matter, 
how the integral module of the uniporter is shifted between the MCU complexes, 
dependent on the phospholipid environment. Thus, the interaction of the pore-forming 
subunit MCU and its regulator EMRE is not affected in TAZ KO MEF mitochondria 
(Figure 3.8). In addition, the interaction of newly in-vitro imported MCU with 
endogenous EMRE is not affected in TAZ KO mitochondria (Figure 3.19). The same 
finding has been observed by in-vitro import of EMRE with exogenous, FLAG-
tagged MCU (Figure 3.17). Imported EMRE assembles with MCU and forms the two 
kDa MCU complexes with the characteristic complex ratio pattern in WT and TAZ 
KO MEF cells. The TIM23 complex-dependent protein import machinery is not 
affected in TAZ KO MEF cells. The protein steady state levels of core translocase 
constituents (Tim23, Tom and Tim22 complex) are not altered in TAZ KO MEF cells 
as well as the structural integrity of translocase complexes (Figure 3.14). The in-vitro 
import of the preproteins EMRE and the motor-dependent, matrix-targeted OTC are 
not affected in isolated TAZ KO mitochondria (Figure 3.16), whereas the mature 
form of in-vitro imported MCU in TAZ KO is reduced (Figure 3.18). The paradox is, 
that the protein steady state levels of MCU, EMRE and other uniporter constituents 
are not affected in TAZ KO MEF cells (Figure 3.1), whereas the MCU import seems 
to show a reduction (Figure 3.18). The reduced amount of matured MCU after in-vitro 
import cannot be explained by an increased turnover of newly imported MCU (Figure 
3.20). The insertion of 2-TMD-containing proteins into the inner mitochondrial 
membrane in general (Figure 3.21) and the lack of one constituent on the MCU pore 
in TAZ KO (MICU1) cannot explain the reduced amount of mature MCU (Figure 
3.22). However, MCU imports into CCCP-titrated WT mitochondria showed, that 
MCU imports are highly membrane potential-sensitive in comparison to the model 
precursor import of OTC (Figure 3.23). The reduced MCU import into TAZ KO 
mitochondria does not fit to the unaltered MCU steady state levels in WT and TAZ 
KO MEF cells. MCU protein steady state levels in BTHS mouse heart mitochondria 
are reduced instead (Figure 3.29). This phenotype is not observed in BTHS mouse 
liver or brain (Figure 3.29). MCU complexes in cardiac BTHS mouse mitochondria 
are reduced, but do not display a changed complex organization in tafazzin-lacking 
mitochondria (Figure 3.30). MCU complexes in BTHS mouse brain and skeletal 
muscle undergo a MCU complex ratio shift from WT to BTHS, comparable to WT 
and TAZ KO MEF cells (Figure 3.26). 
6 Future perspectives 
 
6.1 MCU reduction in BTHS cardiac mitochondria 
 
The reduction of MCU protein levels in BTHS mouse hearts could be caused by an 
increased turnover of newly translated MCU protein or an import defect into 
mitochondria. The decreased levels of MCU are also found in BTHS patient-derived 
induced pluripotent stem cell (iPSC) cardiomyocytes. To study the turnover of MCU 
protein in iWT and iTAZ cardiomyocytes, they can be treated with emetine, which 
inhibits cytosolic translation. iPSC cardiomyocytes are a suitable model to study 
mitochondrial calcium uptake by ratiometric calcium sensors, which is difficult to 
perform with isolated mitochondria from mouse tissues. It would be interesting to 
investigate, if cardiac BTHS mitochondria show decreased mitochondrial calcium 
uptake. 
 
6.2 MCU interaction partners and complex composition 
 
The MCU complex composition of the MCU-2 and MCU-3 in MEF cells could not be 
fully clarified. The putative inhibitory function of MCUb could affect calcium uptake 
into mitochondria. Downregulation of MCUb and MCUR1 via RNAi would give 
more information about MCUb- and MCUR1-containing MCU complexes on 2D-
BN-SDS-PAGE. MCUb and MCUR1 antibodies will be tested for native Co-IP to 
investigate both, the interaction with other MCU constituents in TAZ KO and the 
determination of MCUb/MCUR1-containing MCU complexes by depletion 
coimmunprecipitation. The importance of this question was explained by several 
findings of the last years, that the MCU complex composition and presence/absence 
of MCU components always determine the uniporter activity directly. Altered 
mitochondrial calcium homeostasis in BTHS could affect putative calcium-dependent 
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